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ZUSAMMENFASSUNG 
 
Das Kolonkarzinom gehört zu den am häufigsten vorkommenden Krebsarten 
weltweit. Etwa 130 000 Menschen werden jährlich allein in den USA mit 
Dickdarmkrebs diagnostiziert. Statistisch gesehen werden 45 % von den 
diagnostizierten Menschen an den folgen des Dickdarmkrebs sterben. Die Chancen 
auf eine vollständigen Heilung hängt entscheidend von dem Stadium des Tumors 
ab zum Zeitpunkt der Diagnose. 
CEA wurde bereits 1965 zum Ersten mal als oncofetales Antigen von Gold und 
Freedman beschrieben (GOLD, P. and FREEDMAN, S., 1965). CEA ist ein 
Glykoprotein, hat eine Grösse von ca. 180 kD und gehört zu der Familie 
Immunglobulingene. Es ist das Älteste bekannte tumorassoziierende Antigen. CEA 
ist in den vielen Karzinomen, wie zum Beispiel im Karzinomen des Dickdarms, der 
Brust, oder der Lunge, überexprimiert.  
Klinische Studien zeigen, dass es eine Korrelation zwischen dem Tumorstadium 
und der allgemeinen Prognosis von Krebspatienten und der Konzentration von CEA 
im Serum gibt (GREM, J., 1997). Jedoch ist die Funktion von CEA und sein 
eventueller Einfluss an der Metastasierung von Kolonkarzinom Zellen noch unklar.  
In der Literatur ist CEA bereits als ein Adhäsionsmolekül beschrieben worden 
(BENCHIMOL, S., et al. 1989, STANNERS, C.P., et al. 1998 und ZHOU, H., et al. 
1993). Es wurde postuliert, dass Zellen, die leicht miteinander aggregieren, somit 
eine bessere Überlebenschance in der Blutzirkulation haben als Einzelzellen. Zum 
anderem wurde gezeigt, dass CEA an Kupffer Zellen der Leber bindet und die 
Freisetzung von Zytokinen stimuliert (GANGOPADHYAY, A., et al., 1998 und 
EDMINSTON, K., et al. 1997). Eine andere Forschungsatbeit postuliert eine 
mobilitätsfördernde/ metastasierende Funktion von CEA (VON KLEIST, S., et al. 
1995). 
 
Das Ziel dieser Arbeit war die Funktion von CEA und seine Bedeutung bei der 
Metastasierung zu klären. Um diese Fragestellung zu klären, haben wir die humane 
Dickdarmkrebszellinie HT29 mit Ribozymen (gerichtet gegen die mRNA von 
CEA) unter der Kontrolle eines Tet-off Promoter-Systems transfiziert.  
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Unter normalen Bedinnungen wird das Ribozym kontinuierlich synthetisiert, was 
zur einer Reduzierung der CEA Expression führte. Bei Hinzugabe von Tetrazyklin 
wird die Synthese des Ribozyms blockiert und eine normale (erhöhte) CEA 
Expression ist die Folge.  
Diese Methode bringt uns drei wesentliche Vorteile gegenüber herkömmlichen 
Methoden: 1) die Benutzung von Ribozymen ermöglicht eine hohe spezifische 
Inhibition des Zielmoleküls. 2) Mit Hilfe des Tet-off Promoter-Systems ist es 
möglich, die Konzentration von CEA innerhalb eines Zellklones zu kontrollieren. 
3) Es ermöglicht die Untersuchung von CEA innerhalb eines pathophysiologischen 
Kontextes.  
Mit Hilfe des Tet-off Systems wurde die Expression von CEA um 50% auf der 
RNA sowie der Protein Ebene reguliert. 
 
Zur Untersuchung des Einflusses von CEA auf die Aggregatenbildung von HT29 
Zellen, führten wir einen Aggregationsassay durch. Wir konnten zeigen, dass bei 
Reduktion der CEA Expression die Aggregatenbildung von HT29 Zellen deutlich 
geringer war, als im Vergleich zu den HT29 Zellen mit normaler CEA Expression. 
Wir konnten somit die Funktion von CEA als ein homophile Adhäsionsmolekül 
(Tumor-Tumor Aggregatenbildung) zeigen.  
Zur Identifikation CEA regulierter Gene, wurde ein cDNA Microarray 
durchgeführt. Der cDNA Microarray bestand aus 588 Gene (unterteilt in 13 
Gruppen), die mit der Karzinogenese assoziiert sind. 134 von 588 Genen wurden 
durch CEA beeinflusst. Praktisch wurden Gene von allen 13 Gruppen beeinflusst - 
unter anderem Gene die zu den Apoptose regulierende Genen gehörten, wie auch 
Gene die zu den Zellzyklen regulierenden Genen gehörten. 
 
Zur Überprüfung der Korrelation zwischen der Genexpression im cDNA Array und 
dem Phenotyp von HT29 Zellen in vitro, haben wir mit Hilfe von AnnexinV-
Färbung die Apoptoserate von HT29 Zellen mit normaler und reduzierter CEA 
Expression verglichen.  
Unter semikonfluenten Wachstumsbedinnungen war kein Unterschied in der 
Apoptoserate zwischen HT29 Zellen mit normaler CEA Expression und reduzierter 
CEA Expression beobachtet. Die Änderung der Wachstumsbedinnungen (z.B. 
Wachstum unter konfluenter Bedinnungen), führte zum Anstieg der Apoptoserate 
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in HT29 Zelllinie mit reduzierter CEA Expression signifikant, wobei die 
Apoptoserate der Zellen mit normaler CEA Expression nahezu gleich blieb. 
Dasselbe Ergebnis erhielten wir, durch Inkubation der HT29 Zellen entweder mit γ-
Interferon , oder 5-FU. Zellen mit normaler CEA Expression hatten eine niedrigere 
Apoptoserate, als die Zellen mit reduzierter CEA Expression.  
CEA hatte somit eine protektive Wirkung gegen Apoptose unter verschiedenen 
Stressbedinnungen.  
 
Zur Untersuchung des Einflusses von CEA auf die Metastasierungsrate von HT29 
Zellen in vivo, injizierten wir über die Schwanzvene von Nacktmäusen HT29 
Zellen - einmal HT29 Zellen mit normaler CEA Expression (Tetrazyklin behandelt) 
und einmal HT29 Zellen mit reduzierter CEA Expression. 1 Stunde nach der 
Injektion von HT29 Zellen waren in der Lunge bei beiden Gruppen HT29 Zellen 
sichtbar. Quantitativ war kein Unterschied zwischen Zellen mit normaler CEA 
Expression und Zellen mit reduzierter CEA Expression zu sehen. Nach 24 Stunden 
waren optisch keine Tumorzellen in beiden Gruppen mehr sichtbar. Nach 6 
Wochen jedoch waren in den Mäusen, die weiterhin mit Tetrazyklin behandelt 
wurden (normale CEA expression), Metastasen sichtbar, wärendessen in den 
Mäusen die nicht mit Tetrazyklin behandelt wurden (reduzierte CEA expression) 
eine wesentlich geringere Anzahl von Metastasen vorhanden waren. Das Ergebnis 
des Tierversuches deutet daraufhin, dass die Funktion von CEA als 
Aggregationsmolekül in den Prozess der Metastasierung nicht entscheidend ist, 
jedoch der Wachstumsvorteil der HT29 Zellen mit erhöhter CEA Expression 
(niedrigere Apoptoserate) gegenüber den Zellen mit reduzierter CEA Expression 
(erhöhte Apoptoserate) eine wesentliche Rolle spielt. 
 
Zur Untersuchung, ob CEA fähig ist mit Proteinen zu interagieren, die eventuell 
Einfluss auf die Signaltransduktion von Dickdarmkrebszellen hat, haben wir eine 
Phage-Display-Analyse durchgeführt. Mit Hilfe einer cDNA Bibliothek –erstellt 
aus der Dickdarmkrebszelllinie LS174T – haben wir nach Kanditaten gesucht, die 
eventuell Einfluss auf die Signaltransduktion von Dickdarmkrebszellen hat. 
Insbesondere haben wir nach Kanditaten gesucht, die in Verbindung zur Apoptose 
stehen. CEA war fähig mit verschiedenen Proteinen zu interagieren und wir 
 5
konnten auch ein Protein identifizieren, dass in Verbindung zur Regulation der 
Apoptose steht. 
Diese Arbeit zeigt, dass CEA ein multifunlktionelles Molekül ist. Erstens, wir 
konnten zeigen, dass CEA als ein homophiles Adhäsionsmolekül fungiert, welches 
die Aggregation von HT29 Zellen fördert. Des weiteren konnten wir zeigen, dass 
CEA ein protektives Molekül gegen Apoptose ist und dadurch die Metastasierung 
von HT29 Zellen in Nacktmäusen fördert. Zuletzt konnten wir mit Hilfe von Phage 
Display nachweisen, dass CEA fähig ist mit anderen Proteinen zu interagieren und 
somit auch Einfluss in die Signaltransduktion hat. 
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ABBREVIATIONS 
 
 
5-FU = 5 fluoruracil 
APC = Adenomatous polyposis coli  
ATCC = American type culture collection 
bp = base pair 
BSA = Bovine serum albumin 
cDNA = copy deoxyribonuclein acid 
CEA = Carcinoembryonic antigen 
CEACAM = carcinoembryonic antigen cell adhesion molecule 
CMV = cytomegalovirus 
DAB = 3,3’-Diamonobenzidine 
DCC = deleted in colon cancer 
dCTP = deoxycytosin triphosphate 
ddH20 = double distilled water 
DEPC = Diethyl Pyrocarbonate 
DNA = deoxyribonucelic acid 
Dnase = Deoxyribonuclease  
dNTP = deoxynucleoside triphosphate  
E. coli = Escherichia coli 
EDTA = Ethylenediaminetetraacetic acid 
FACS = fluorescence activated cell sorting 
FAP = Familial adenomatous polyposis 
FBS = fetal bovine serum 
GAPDH = Glyceraldehyde-3 phosphate dehydrogenase 
GPI = Glycosyl phosphatidyl inositol  
GTPase = Guanin triphosphatase 
H2O2 = superperoxide 
HNPCC = Hereditary nonpolyposis colorectal cancer 
IFN-γ = Interferon gamma 
Ig = Immunoglobulin 
IGF = Insulin-like growth factor 
IL = Interleukine 
IMEM =  
kDA = kilo Dalton 
LB media = media for bacteria culture 
MCC = mutated in colon cancer 
MHC = Major histocompatibility complex  
mM = milli Molar 
mRNA = messenger ribonucleic acid 
Mw = Molecular weight 
NCA = Non-specific crossreacting antigen,  
nt = nucleotide 
PBS = phosphate buffered saline 
PBST = Phosphate buffered saline with tween 
PCR = Polymerase chain reaction 
PI = probidium iodid 
PS = Phosphatidylserine  
PSG = Pregnancy specific glycoprotein  
pTET = ribozyme expression plasmid 
RNA = ribonucleic acid 
Rz = ribozyme 
SDS =  Sodium dodecyl sulfate 
SSC = Saline-sodium citrate 
tet = Tetracycline 
TNF = Tumor necrosis factor 
tTA = tetracycline transactivating 
UV = Ultra violet 
VEGF = Vascular endothelial growth factor 
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1. INTRODUCTION 
 
Peyton Rous opened his Nobel lecture of 1966 with the following passage: 
“Tumors destroy man in a unique and appalling way, as flesh of his own flesh 
which has somehow been rendered proliferative, rampant, predatory and 
ungovernable. [Tumors] are the most concrete and formidable of human maladies, 
yet despite more than 70 years of experimental study they remain the least 
understood... What can be the why for these happenings ?”  
35 years after the speech of Rous a lot of progress and knowledge has been 
achieved in the field of cancer research. However, cancer is still a major problem, 
and one of the leading causes of death. It manifests itself as a population of cells 
that have lost their normal controls of growth and differentiation. 
 
1.1. Colon Cancer 
 
At least 50% of the western population develops a colorectal tumor by the age of 70 
and in about 1 in 10 of these individuals, progression malignancy ensues. 
Colorectal cancer (CRC) accounts for approximately 1 of every 10 deaths from 
carcinoma and is as a result the second leading cause of cancer death (10 to 12%; 
HARMS, B. A. et al. 2001). Approximately 130.000 new cases will occur every 
year in the United States, alone, with many more cases worldwide (HARMS, B. A. 
et al. 2001), and 45% of these patient will die from their disease often despite the 
apparent complete surgical resection of their local disease (FEARON, E. R. 1995). 
40 to 50% of colorectal cancer patients won’t survive longer than 5 years. The main 
reason for mortality is metastatic disease which occurs most often in the liver, 
followed by the lung. The most important factor predicting recurrence is the stage 
of tumor at the time of resection. Patients whose tumors have only penetrated into 
the mucosa of the bowel but not further and have not spread to local lymph nodes 
(stage I or Dukes A) typically have a cure rate in of >90% (MINSKY et al. 1988). 
However, 20% of patients will suffer metastatic relapse when tumors have  
penetrated into, or through the muscularis propria of the bowl wall, but have not 
spread into the regional lymph nodes (tumors of stage II or Dukes B) (MINSKY et 
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al. 1988). If tumor spread is identified in the regional lymph nodes (stage III or 
Duke C) the odds for cure are reduced to 50% (MINSKY et al. 1988).  
 
One of the most important developments in genetics over the past decade has been 
the proof that cancer is, in essence, a genetic disease (VOGELSTEIN, B. and 
KINZLER, K. W. 1996). First, cancer is, for the most part, caused by somatic 
mutations, whereas most of other genetic diseases of mammals are caused solely by 
germ-line mutations. Second, each individual cancer arises not from a single 
mutation, but from the accumulation of several mutations, even though there are 
differences in the amount of mutations needed. Statistical analyses of age-incidence 
curves have suggested three to four successive mutation-like changes for leukemia 
and six to seven for carcinomas (FARBER, E., & CAMERON, R. 1980 and 
KNUDSON, A. 1973). The only known exceptions are found in experimental viral 
oncology, where some of the retrovirus-transduced oncogenes can cause tumors in 
a single step (KLEIN, G., & KLEIN, E. 1985).  
The most devastating aspect of neoplasia, however, is the spread from a primary 
site to distant organs (metastasis). Metastasis comes from Greek (from methistanai, 
to change), which literally means change of position, state, or form, as a transfer of 
a disease (-or disease-producing agency) from the site of disease to another part of 
the body. It was Virchow who, already in 1858 realized and coined the Latin 
aphorism by which the cell theory became known: omnis cellulae cellula – “all 
cells come from cells”. Virchow pointed out that the cellular components of 
metastatic cancer generally resemble those of the primary tumor, as if they all 
might be relatives. The spread of tumors throughout the body is a 
pathophysiological process of profound clinical significance. The lethality of 
malignant neoplasms is attributable directly to their ability to develop secondary 
growths in organs at a distance from the primary tumor mass. The primary or 
localized tumor mass will usually pose little threat to the well being of the patient, 
unless it is located in a critical site within an organ such as the brain. In a case of a 
localized tumor, it is normally very probable that surgery will be curative at that 
stage. 
 
Colorectal cancer develops through several histological well defined stages, 
reflecting the sequential acquisition of genetic alteration. Beginning with the 
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general mechanisms of oncogenesis of colorectal cancer, it is known that both 
inherited and environmental factors play an important role in carcinogenesis. 
Mutations in certain genes may be inherited, termed germ line mutations, or 
acquired, termed somatic mutations. Molecular experimental studies have 
demonstrated, that the progression of colorectal cancer from adenoma to carcinoma, 
results from the accumulation of molecular genetic alteration, involving mainly 3 
factors: I) activation of oncogenes; II) inactivation of tumor suppressor genes; and 
III) abnormalities in genes involved in DNA mismatch repair (BRESALIER, R. S. 
et al. 1998).  
Several frequently mutated genes have been identified which probably contribute to 
the development of both hereditary and somatic cancer (FEARON and 
VOGELSTEIN, 1990). Mutations have been able to observe in the earliest 
detectable stages of cancer development and it seems that specific genes tend to be 
mutated in a given order. 
 
Hereditary and non-hereditary colorectal cancer 
 
It is believed, that approximately 15-20% of all colorectal carcinomas cases involve 
a hereditary component (KINZLER, K. W. & VOGELSTEIN, B. 1996). On the 
contrary, approximately 80% of colorectal cancer is considered ‘sporadic’. Like all 
cancers, ‘sporadic’ colorectal cancer is the result of the accumulation of genetic 
mutations. Although any one gene mutation eventually can lead to cancer, research 
by Kinzler and Vogelstein has identified that there are at least seven genetic events 
that are required for colorectal cancer development and that these events occur most 
likely in a preferable order (KINZLER, K. W. & VOGELSTEIN, B. 1996). 
In 1990, Fearon and Vogelstein proposed a model of successive genetic changes 
leading to colorectal cancer, in which a number of genes were involved, including 
the APC gene, k-ras, DCC gene and p53 (FEARON and VOGELSTEIN, 1990). 
Mutations in the APC gene are responsible for the FAP syndrome, which will be 
discussed in the hereditary colorectal cancer section below. In ‘sporadic’ colorectal 
cancer, such mutations or deletions also appear and are found to be essential in the 
beginning of the cascade in early adenoma formation. 
The k-ras is one of the three mutant ras oncogenes that are found in human tumors. 
K-ras is found in approximately 40% of colorectal cancers. Mutation in the k-ras 
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oncogene normally appears at the border of small and large adenomas after APC 
loss, but before DCC and p53 inactivation and leads to activation of a tyrosin 
kinase cascade, like for example p21 activation (BOS, J. L., et al. 1987 and 
FORRESTER, K. et al 1987). 
In 70 to 80% of colorectal cancer cases the long arm of chromosome 18 (containing 
the DCC gene) is deleted (VOGELSTEIN, B. et al. 1989). This deletion seems to 
appear a little later than APC and k-ras, but earlier than p53 mutations. Also this is 
happening at the border of small and large adenomas. The DCC gene is a very large 
gene, and loss of function of this gene seems to impair normal cell adhesion. Some 
studies have shown that normal DCC is able to stop a cell in G2/M of the cell cycle 
and induce apoptosis (CHEN, Y. O. et al. 1999). 
Regarding the p53 gene, in most cases of colon cancer tissues (75 to 80%) at least 
one of the copies (which are located on chromosome 17q) of this region is deleted 
and the other allele found to be mutated (KINZLER, K. W. et al. 1991). It is 
hypothesized that a p53 mutation appears in the later stages of tumor progression 
(late adenoma or early carcinoma) (DICATO, M. et al 2000). 
In additions to the mutations in those genes mentioned above, there are other 
factors that are probably implicated in the cascade leading from normal colonic 
cells to invasive colon cancer. Some of them are known, such as MCC (mutated in 
colon cancer), but their exact role remains elusive. Some oncogenes like c-myc and 
c-myb, are amplified in some tumors and they are shown to induce transformation, 
however, their clinical relevance is not yet certain (D’EMILIA, J., et al 1989 and 
ERISMAN, M. D., et al. 1988). 
Regarding hereditary colorectal cancer, two of the best defined familial forms of 
hereditary colorectal cancer are FAP (Familial Adenomatous Polyposis) and 
HNPCC (Hereditary Nonpolyposis Colorectal Cancer). 
FAP is an autosomal, dominantly inherited disease that affects about 1 in 7000 
individuals. Patients with FAP typically develop hundreds to thousands of, mainly 
benign, colorectal tumors (called adenomas or adenomatous polyps) during their 
second and third decades of life. Although these benign tumors are not individually 
life threatening, their large numbers virtually guarantee that some will progress to 
malignant lesions. 
Adenomatous polyposis was first observed in the mid 18th century and its inherited 
nature was already recognized in1900 (KINZLER, K. W. and VOGELSTEIN, B. 
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1996). But it wasn’t until the last decades that the cause of this disease was 
discovered. The first clue was a cytogenetically evident interstitial deletion of 
chromosome 5q in a patient with polyposis (HERRERA, L. et al. 1986). A Year 
later a tight linkage of the disease to markers on chromosome 5q21 was 
demonstrated by Bodmer et al and Leppert et al. (BODMER, W. et al. 1987 and 
LEPPERT, M. et al. 1987) and it became possible to identify the adenomatous 
polyposis coli (APC) gene, and to proof that this gene caused FAP (GRODEN, J. et 
al. 1991 and NISHISHO, I. et al. 1991).  
The normal function of the APC gene is believed to be tumor suppression. The 
most common mutation results in a ‘stop codon’ that leads to a truncated protein 
product (POWELL, S. M. et al. 1993). More than 300 different germline APC 
mutations have been described in FAP patients and there are evidence for 
correlation between the exact location of the mutation on the gene and the resulting 
phenotype expressed (OLSEN, S. J. et al. 2000).  
Hereditary nonpolyposis colorectal cancer is the most common hereditary colon 
cancer syndrome. It is dominantly expressed and accounts for 5-10% of all 
colorectal cancer cases (BURKE, W. et al. 1997). Despite its name, it also is 
characterized by the presence of colon polyps. The number of polyps present in 
hereditary nonpolyposis colorectal cancer is much less than those seen in FAP, that 
is because, in contrast to FAP, patients with HNPCC do not have abnormal APC 
alleles and therefore do not develop extensive polyps (HARMS, B. A. et al. 2001). 
However, although their lesions are more commonly right sided, clinically they 
represent identically to patients with sporadic colon carcinoma. The exact definition 
of HNPCC is problematic owing to various clinical phenotypes and the multiplicity 
of associated genes. 
 
Treatment of colorectal cancer 
 
The main form of treatment for colorectal cancer is surgical resection (ROUGIER, 
P. and MITRY, E. 2000). Nevertheless, as many as 30% of patients who undergo 
“successful” surgery for colon carcinoma will develop recurrent disease, either 
locally or at distant sites, within 5 years of surgery (HARMS, B. A. et al. 2001). 
Additional systemic treatment, known as “adjuvant” therapy is nowadays widely 
used. However, there are variabilities in the use of adjuvant therapy after curative 
 15
surgery. In the United States it is used very selectively for patients with stage B2 
colorectal carcinoma, and is generally recommended for patients with lymph node 
involvement (Dukes C) without other significant comorbidities, while in Japan for 
example, adjuvant therapy has been used for all patients except those with stage A 
tumors (TOMINAGA, T. et al. 1996).  
5-Fluorouracil (5-FU), a thymidylate inhibitor and analog of uracil, is the main 
chemotherapeutical agent in the treatment of colorectal cancer (HARMS, B. A. et 
al. 2001). It is an analog of uracil, and it has been used now already for more than 
40 years. However, used alone it has limited activity. Nevertheless, improvements 
have been made in the last 15 years that justify its role as the main agent.  
In the United States the most widely used adjuvant treatment for metastatic 
colorectal cancer is the combination of 5-FU plus leucoverin (MOERTEL, C. G. 
1994). Other combination therapies used are 5-FU in combination with Oxalplatin, 
or 5-FU in combination with Irinotecan, a topoisomerase 1 inhibitor (ROUGIER, P. 
and MITRY, E. 2000). 
 
 16
1.2. Carcinoembryonic Antigen (CEA) 
 
Little more than 35 years ago two groups, Gold and Freedman in Canada, and von 
Kleist and Burtin in France, described independently the presence of a tumor 
associated antigen in colonic carcinomas and their metastases (GOLD, P. and 
FREEDMAN, S. O. 1965, and VON KLEIST, S. BURTIN, P. 1966). This tumor 
associated antigen was called carcinoembryonic antigen (CEA) because it was also 
shown to be present in the homologous embryonic tissues. The name is strictu 
senso incorrect, because CEA is produced not only during the first trimester of 
gestation, but throughout pre-natal life and even after birth.  
CEA is physiologically found to be expressed apical-wise of glandular epithelial 
tissue and it is also strongly expressed by the intestinal mucosa (ÖBRINK, B. 
1997). CEA has been shown to bind to certain strains of Escherichia coli 
(THOMPSON, J. A. et al. 1991). According to Thompson et al. this binding may 
facilitate bacterial colonization of the intestine (THOMPSON, J. A. et al. 1991). 
Hammerstrom, on the other hand suggested that CEA may play a role in protecting 
the colon from microbial infection, possibly by binding and trapping infectious 
microorganisms (HAMMERSTROM, S. 1999). 
 
Analysis of the amino acid sequence of CEA (and other members of the CEA 
family) revealed, that CEA belongs to the immunoglobulingene-superfamily 
(Figure1). 
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Figure 1: The CEA family. CEA itself is anchored with a GPI anchor to the cell 
membrane (compared to BGP for example CEA does not have a transmembrane and a 
intercellular domain). 
 
 
 
 
29 different genes and pseudogenes have been identified which are related to CEA. 
All of these genes are clustered to the chromosome 19q13.2 within a region of 1.8 
Mb. The CEA family can be divided into three subgroups. First, the CEA subgroup, 
containing 12 members, where 7 genes are expressed and 5 are pseudogenes. 
Second, the pregnancy specific glycoprotein (PSG) group consisting of 11 
expressed genes. And third, a group of six pseudogenes (Hammerstrom, S. 1999). 
All members of the CEA subgroup, CEACAM1 (biliary glycoprotein, BGP), 
CEACAM3 (CGM1) and CEACAM4 (CGM7), have a transmembrane domain 
followed by a cytoplasmic domain, while CEACAM5 (carcinoembryonic antigen, 
CEA), CEACAM6 (non-specific crossreacting antigen, NCA), CEACAM7 
(CGM2) and CEACAM8 are anchored in the cell membrane via a glycosyl 
phosphatidyl inositol (GPI) moiety (Hammerstrom, S. 1999).  
CEA is a glycoprotein which contains approximately 50% carbohydrate and has a 
molecular weight of approximately 180 kDa. It consists of a N-terminal domain of 
108 amino acids homologous to the Ig variable domain (IgV-like) and six domains 
homologous to the Ig constant domain of the C2 set (IgC2-like). The six constant 
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domains are divided in 3 type A IgC2 domains containing each 93 amino acids and 
3 type B IgC2 domains which contain 85 amino acids. A signal peptide of 34 amino 
acids precedes the N-domain but is cleaved off from the mature protein following 
transport to the cell membrane. 
CEA is taken rapidly up from the circulation by the liver and catabolized in the 
lysosomes. Peter Thomas group studied the clearance of CEA in rat liver. They 
found out, that about 70% of 125-labeled intact CEA was cleared by the rat liver 
already within 1 hour and that CEA is probably initially taken up by Kupffer cells, 
where it is modified for removal and transferred afterwards to the hepatocytes. 10% 
of CEA added to an isolated perfused liver appeared in bile (THOMAS, P. et al. 
1983). 
 
CEA is the oldest known and most frequently found tumor associated antigen in 
cancer such as colorectal-, gastric-, pancreatic, lung-, and breast cancer. While CEA 
is nowadays the most commonly used tumor marker for malignancies of the 
gastrointestinal tract, it has never proved useful as a screening test for early cancer 
(HARMS, B. A. et al. 2001). Primary colorectal cancers are commonly CEA 
positive. In fact 90% of these tumors can be shown to produce CEA (GOLD, P. et 
al. 1978 and CUTAIT, R. et al. 1991). While CEA is found on the apical side of 
normal epithelial cells it has lost its polarized expression in malignant tumors. 
Furthermore it is secreted in the extracellular space. Thereby, it has access to blood 
capillaries, and hence, can be found in the serum. CEA can be used as a tumor 
marker, by measuring CEA levels in the serum. However, low levels of CEA can 
also be found in blood of healthy people and elevated levels can occur under 
various non-malignant disorders such as chronic inflammatory diseases. CEA can 
be modestly elevated in about 19% of smokers who do not have cancer and in 3% 
of normal population. Certain benign liver diseases impair liver function, and thus, 
the clearance of CEA. These false elevation, however, are almost always less than 
10ng/ml and remain stable during serial testing, in contrast to CEA produced by 
recurrent tumor. Therefore, in patients with appropriate symptoms and a highly 
increased concentration (e.g. >5 times the upper limit of normal) should be 
considered suggestive for the presence of cancer in that particular patient. 
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Multiple studies have shown that patients with high preoperative concentrations of 
CEA have a worse outcome than those with low concentrations of the marker 
(GREM, J. 1997). 
When CEA levels are elevated in patients, preoperatively for the primary colorectal 
cancer, they predict a worse prognosis. The sensitivity of CEA as a monitoring test 
varies from 43 to 89%, with a specificity of 70 to 90%. Elevation of CEA in 
primary tumors correlates with Dukes’ stage, 45% of Dukes C tumors and 25% of 
Dukes B tumors (HARMS, B. A. et al. 2001). 
Persistent elevation of CEA 1-month postoperatively suggests the presence of 
occult metastatic disease and predicts for early development of recurrence. For 
those patients with a normal preoperative CEA and patients whose CEA returns to 
normal within 4 to 6 weeks of the resection of their primary tumor, a CEA increase 
is most often the first warning of metastatic disease. A significant and progressively 
increasing CEA is associated with 75% of metastatic colorectal cancer (MAYER, 
R. J., et al. 1978). 
 
Biological function of CEA 
 
Even though it has been shown that CEA correlates with stage of tumor, the role of 
CEA in malignant conditions is barely understood. Ever since it was discovered 
that the CEA gene family is a member of the Ig-supergene family, to which belongs 
a whole array of prominent molecules involved in cell-adhesion or cell/cell- 
recognition (e.g. ICAM-1, or ICAM-2), studies have been done to determine the 
role of CEA as an adhesion molecule. Benchimol et al. suggested CEA to function 
as an intercellular (homophilic) adhesion molecule. They found that aggregate 
formation of single cells correlates with the level of CEA. Adding of an anti-CEA 
antibody inhibited aggregate formation. However, they could not exclude that 
adhesion might also rely on interactions with other CEA family members such as 
CEACAM6 or CEACAM1. To exclude the interaction of CEA with other CEA 
family members, they transfected chinese hamster ovary cells, which do not express 
CEA-related molecules, with a CEA expression vector. In doing so, they could 
prove an adhesive function of CEA (BENCHIMOL, S. et al. 1991). Because 
alterations in cell adhesion are causally involved in cancer invasion and metastasis, 
it was suggested that CEA may play a role in these processes. However, Landuzzi 
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et al. did similar studies using a rhabdomyosarcoma cell line and demonstrated 
results which were the opposite of those demonstrated by Benchimol et al. 
(LANDUZZI, L., et al. 1996). CEA overexpressing cells showed reduced adhesion 
and a reduction of the metastatic rate, suggesting that CEA molecules could 
interfere with adhesion maintained by other adhesion molecules, such as E-
cadherin, MUC18 and N-CAM (LANDUZZI, L., et al. 1996). 
Beside homophilic cell adhesion function, CEA has also been implicated as a 
heterophilic intercellular binding molecule which mediates the colonization of liver 
and lung by colon cancer cells. Recently, Hostetter et al. showed that after 
transplantation of colorectal tumors into nude mice the number of liver metastases 
increased from 2% to 48% following injection of mice with CEA (HOSTETTER, 
R.B. et al 1990). There is, however no direct evidence that CEA causally was 
involved in the process of metastasis. Thomas et al. overexpressed MIP-101, a 
poorly differentiated human colon cancer cell line, with CEA. They found an 
increased metastatic rate from high CEA expressing clones and described strong 
CEA staining of Kupffer cells adjacent to tumor cells in the liver (THOMAS, P. et 
al. 1995). The potential interaction of Kupffer cells and CEA expressing tumors 
was also described by Bayon et al. They injected a syngeneic colon cancer cell line 
into a mesenteric vein of rats. They suggested that Kupffer cells play a relevant role 
in arresting circulating tumor cells at the liver sinusoid, maybe through binding of 
CEA to Kupffer cells (BAYON, L. G., et al. 1996).  
Further studies suggest that CEA might increase the metastatic capability of cancer 
cells by immunemodulation. It was found that CEA could induce the production of 
cytokine, by binding of CEA to Kupffer cells. Binding of CEA to HnRNP M4, a 
recently described receptor of CEA on Kupffer cells (BAJENOVA, O. V. et al. 
2001), was shown to induce the release of IL-6, TNF-α, IL-1α and IL-1β. This 
might downregulate the immune response against tumor cells and thereby enhance 
the metastatic rate in vivo (EDMINSTON, K. et al. 1997). The release of cytokines 
from Kupffer cells (caused by binding of CEA to Kupffer cells) might also modiy 
the adhesion molecule pattern of endothelial cells in a way that colon cancer cells 
can better bind and, thereby, enhance their metastatic potential 
(GANGOPADHYAY, A. et al. 1998). 
Some groups have shown that CEA modulates the susceptibility of human 
colorectal carcinoma cells to cytotoxic lymphocytes (RIVOLTINI et al. 1992; 
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KAMMERER and VON KLEIST, 1994). Kammerer and von Kleist further 
demonstrated, that the density of the CEA molecules on the tumor cell surface has a 
determining influence on its protective function (for example protection from LAK-
cell lysis), whereas CEA released by tumor cells had no protective effect for CEA 
negative cells (KAMMERER and VON KLEIST, 1996). 
Finally, Ordonez et al. reported that overexpression of CEA can protect tumor cells 
from undergoing anoikis, i.e. apoptosis induced by loss of cell contact with the 
extracellular matrix (ORDONEZ, C. et al. 2000). 
 
Even though a lot of functions have been implicated for CEA, the role of CEA in 
normal and pathological human physiology remains unknown. The purpose of this 
study was to determine the role of CEA for growth and metastatic behavior of colon 
cancer cells. If CEA is involved in the pathway of metastasis the next question 
would be how.  
We assume that CEA’s function is tissue type dependent and depends on the 
interaction with other molecules, either with cancer cells, or with its 
microenvironment. In order to define the specific function of CEA within its 
pathophysiological context we choose CEA-targeting ribozymes under control of a 
tet-off promoter system.  
 
CMV-minor Gene of intereste.g. Ribozyme
Ribozyme
CMV-Promoter tet-A 
+ tetracycline
Te
t-A
CMV-minor Gene of intereste.g. Ribozyme
Tet-A
 
CMV-Promoter tet-A 
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pUHG15-1 pUHC13-3
 
Figure 2: The tet-off system. Tetracycline binds to the Tet-A protein causing its change of 
confirmation. The Tet-A protein is no longer able to bind to the CMV-minor promoter region 
resulting in blocking of ribozyme synthesis. 
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This model has three major advantages compared to other methods used before. 
First, because of the high specificity of ribozyme molecules (UHLENBECK, O. et 
al 1995) it is able to target exclusively the gene of interest (CEA) and inhibit the 
translation of the mRNA to its actual protein, resulting in a specific inhibition of 
endogenous CEA expression. Secondly, by using the tet-off promoter system the 
CEA levels within identical cancer cell clones can be regulated. And third, by using 
the tet-off system it enables a comprehensive analysis of CEA-mediated effects 
within an intact pathophysiological cellular context. 
In this study we investigated the impact of CEA on tumor cell aggregate formation 
and the impact of CEA-dependent apoptosis on tumor growth in vitro and in vivo. 
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2. MATERIALS AND METHODS 
 
2.1. Materials  
 
2.1.1. Biological materials 
 
Animals 
 
• Ner nude mice       Harlan Sprague- 
        Dawley, Indianapolis, 
        USA 
 
Bacterials 
 
• BLT 5615 (E.coli)      Novagen, Madison, USA 
• DH5α-competent cells (E. coli)    Invitrogen, Rockville, 
        USA 
 
Cell lines  
 
• human colon cancer cell line HT29    ATCC, Manassas, USA 
• murine colon cancer cell line MC38   kindly provided by Dr. 
        J. Shively 
• C15A3 (MC38 cell line transfected to express CEA) kindly provided by Dr. 
        J. Shively 
• HUVEC (human umbilical vein endothelial cells) ATCC, Manassas, USA 
 
Enzymes  
 
• Restriction enzymes (NotI, PSTI, Apa I)   Roche, Indianapolis,  
        USA 
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• Superscript II-Reverse Transcriptase   Invitrogen, Rockville, 
        USA 
• Taq-DNA-Polymerase [5 U/µl]    Invitrogen, Rockville, 
        USA 
 
Nucleic acids 
 
• [α-32P*]-dCTP-Nucleotide    Amersham, Piscataway, 
        USA 
• 100 bp-DNA-ladder     Invitrogen, Rochville, 
        USA 
• dNTP-Nucleotid-Mix, 10 mM     Invitrogen, Rockville, 
        USA 
• pBluescript II KS vector      Invitrogen, Rockville, 
        USA 
• pUHG15-1 and pUHC13-3 expression vector   Dr. Bujard, Heidelberg, 
        Germany 
• Random Hexamers     Invitrogen, Rockville, 
        USA 
• RNA-ladder       Invitrogen, Rockville, 
        USA 
• Salmon sperm      Invitrogen, Rockville, 
        USA 
 
Phage 
 
• T7 Select10-3 (bacteriophage)     Novagen, Madison,  
        USA 
• cDNA library of LS174T      kindly provided by  
        Prof. Dr. Wellstein 
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Antibodies 
 
primary antibodies 
 
• Anti-human CD66e (CBL54),              Cymbus, Biotechnology,  
mouse monoclonal antibody              Hampshire, UK 
 
• Anti-human Cytokeratin (Kl-1)              Cymbus Biotechnology,  
mouse monoclonal antibody               Hampshire, UK 
 
secondary antibodies 
 
• Fluorescein (DTAF)-conjugated AffiniPureGoat  Dianova,Hamburg, 
      Anti-Mouse IgG +IgM        Germany 
• Peroxidase-conjugated AffiniPure Rabbit   Dianova, Hamburg, 
Anti-Mouse IgG + IgM     Germany 
 
Other 
 
• Doxycycline enriched food (220mg/kg)    Bioserv, Frenchtown,  
        USA 
 
2.1.2. Chemicals, reagents and medium 
 
• 1 x Trypsin       Invitrogen, Rockville, 
        USA 
• Agarose        Invitrogen, Rockville, 
        USA 
• Ampicillin       Invitrogen, Rockville, 
        USA 
• Bacto™Agar       Becton&Dickinson,  
        Franklin Lakes, USA 
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• Chloroform       Mallingkrodt   
        Chemicals 
• Cytoseal Mounting medium     Stephens scientific,  
        Kalamazoo, USA 
• DEPC (Diethylpyrocarbonate)    Sigma, St. Louise, USA 
• Diethanolamin      Sigma, St. Louise, USA 
• Dimethylsulfoxide (DMSO)     Invitrogen, Rockville, 
        USA 
• ECL™ Westerb blotting detection reagents   Amersham, Piscataway, 
        USA 
• EDTA (Ethylene diaminetetraacetic acid)  Biofluids, Rockville,  
        USA 
• Ethidiumbromide       Sigma, St. Louise, USA 
• Fetal bovine serum      Invitrogen, Rockville, 
        USA 
• Formaldehyde (37 %)     Mallingkrodt Chemicals, 
• Formamide      Mallingkrodt Chemicals, 
• Geneticin (G418-Sulfat)     Invitrogen, Rockville, 
        USA 
• Glutamine (200mM)      Invitrogen, Rockville, 
        USA 
• Harris Hematoxylin solution    Sigma, Rockville, USA 
• IMEM (cell culture medium)     Invitrigen, Rockville,  
        USA 
• LB broth base      Invitrogen, Rockville, 
        USA 
• LipofectAMINE™     Invitrogen, Rockville, 
        USA 
• Magnesium Chloride (50mM)     Invitrogen, Rockville, 
        USA 
• Metofane (Methoxyfluorane)    Schering Plough, New 
        York, USA 
• Mineral oil      Sigma, St. Louise, USA 
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• PCR 10 x buffer       Invitrogen, Rockville, 
        USA 
• Tris-(hydroxymethyl-)Aminomethan (Tris)  Roche, Madison, USA 
• Trypanblue, (0,4 %)     Invitrogen, Rockville, 
        USA 
• Tween20       Bio-Rad Laboratories, 
        Hercules, USA 
• WST-1        Roche, Madison, USA 
• Zeocin™        Invitrogen, Rockville, 
        USA 
 
2.1.3. Buffers and Solutions 
 
• 1 x PBS (phosphate buffered saline)   Invitrogen, Rockville, 
        USA 
• 10 % SDS (Sodium dodecyl sulfate)   Biofluids, Rockville,  
        USA 
• 20 x SSC        Biofluids, Rockville,  
        USA 
• Tris-HCl 1M (pH 7.5)     Biofluids, Rockville,  
        USA 
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DAB solution                                                                    
180 ml 1 x PBS       
20 ml Tris-HCl (pH 7.5)        
250 mg diaminobenzidine in 50 ml of ddH20     
25 µl H2O2              
 
 
Agarose for Soft agar plates 
100 ml IMEM 
50 ml 2 x IMEM 
20 ml FBS 
50 ml Agarose (1.2g agarose in 50 ml dH2O → autoclave) 
 
 
1 % Agarose Gel 
 1g Agarose  
 99g dH2O 
 1µl Ethidium bromide 
 
 
PCR Reaction Mix (for 11 reactions) 
Water                     368.5µl 
PCR 10 x Buffer    55µl 
MgCl2 (50mM)      33µl 
dNTP (10mM)       11µl 
Primer up               11µl 
Primer down           11µl 
Taq polymerase      5.5µl      
                                45µl → into a PCR tube + 5µl of DNA template 
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2.1.4. Kits 
 
• Apoptag®        Invitrogen, Rockville, 
        USA 
• Atlas™ cDNA expression array     Clontech, Palo Alto,  
        USA 
• Qiaquick gel extraction kit    Qiagen, Valencia, USA 
• rediprime™II (random prime labelling system)  Amersham, Piscataway, 
        USA 
• RNASTAT-60       Tel.Test-Inc.,   
        Friendswood, USA 
• TACS™ Annexin V-FITC kit     Trevigen, Gaithersburg, 
        USA 
• PKH26 Red Fluorescent Cell Linker Kit    Sigma, St. Louise, USA 
• PKH2 Green Fluorescent Cell Linker Kit   Sigma, St. Louise, USA 
 
2.1.5. Equipment and other materials 
 
Equipment 
 
• 0.5-10, 10-100 and 100-1000µl pipettes    Eppendorf, Westbury, 
        USA 
• Dry bath incubator      Fisher scientific, 
         Needham-Heights, USA 
• DU 640® Spectrophotometer     Bekton Coulter,  
        Sommerset, USA 
• EasyCast™ horizontal electrophoresis system  Owl seperation  
        systems, Portsmouth,  
        USA 
• FACStar flow cytometer      Becton & Dickinson,  
        Franklin Lakes, USA 
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• Microcentrifuge 5417 C/R     Eppendorf, Westbury, 
        USA 
• Mini Trans-Blot® Electrophoretic transfer cell  BioRad, Hercules, USA 
• Mini-Protean® II electrophoresis cell    BioRad, Hercules, USA 
• Power Pac 300 (power supply)     BioRad, Hercules, USA 
• RoboCycler® Gradient 40 temperature cycler   Stratagene, La Jolla,  
        USA 
• Rocker II        Boekel, Feasterville,  
        USA 
• Rotina 46 R (cell culture centrifuge)    Hettich, Tuttlingen,  
        Germany 
 
Other materials 
 
• Falcon 100 x 15mm cell culture dishes    Becton & Dickinson,  
        Franklin Lakes, USA 
• Falcon 15ml tubes      Becton & Dickinson,  
        Franklin Lakes, USA 
• Falcon 50ml tubes      Becton & Dickinson,  
        Franklin Lakes, USA 
• Falcon 6-well-cell culture pates     Becton & Dickinson,  
        Franklin Lakes, USA 
• Falcon 96-well-cell culture plates    Becton & Dickinson,  
        Franklin Lakes, USA 
• ImmobilonP™ transfer membrane    Millipore, 
• Nylon membranes (positively charged)    Roche, Madison, USA 
• Falcon T25 and T75 cell culture flasks    Becton & Dickinson,  
        Franklin Lakes, USA 
• Falcon Ten-twenty-nine™ petri dishes    Becton & Dickinson,  
        Franklin Lakes, USA 
• Tris-HCl 4-15 % pre-cast gels     BioRad, Hercules, USA 
• Falcon 0.5ml microcentrifuge tubes    Becton & Dickinson,  
        Franklin Lakes, USA 
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• Falcon 1.5ml microcentrifuge tubes    Becton & Dickinson,  
        Franklin Lakes, USA 
• Falcon 2,5,10 and 25ml aspiration pipettes   Becton & Dickinson,  
        Franklin Lakes, USA 
 
 
2.2. Methods 
2.2.1. Generation of Constructs 
 
The ultimate goal was to generate a clone were we are able to regulate the levels of 
CEA by treating the cells with or without tetracycline. 
Plasmids expressing the tetracycline transactivating (tTA)/VP16 fusion protein 
(pUHG15-1) and the tTA/heptameric operator binding site (tet-O; pUHC13-3) were 
obtained from Dr. Bujard (Heidelberg, Germany). The ribozyme expression 
plasmide (pTET) was derived from pUHC13-3 were the CEA mRNA-targeted 
ribozyme Rz2113 was expressed under the control of the tTA/heptameric operator 
binding site and a cytomegalosvirus (CMV) minimal promoter. (Gossen M. and 
Bujard  H. 1992).  
The major portion of the luciferase gene and the simian virus 40 polyadenylation 
site in the pUHC13-3 plasmid were deleted by HindIII/HpaI digestion and replaced 
with the Rz2113/bovine growth hormone polyadenylation HindIII-PvuII fragment 
from the pRz2113 expression vector (Schulte A et al 1996). The remaining 
luciferase start codon was replaced by SalI/ClaI/HindIII cassette to yield the 
construct pTET/Rz2113. 
The following ribozyme coding sense and antisense oligonucleotides were annealed 
and ligated into the HindIII- and NotI-restriction site of pTET: 
5’agcttTGCTCTTCTGATGAGTTCCGTTAGGACGAAACTATGGAgggcc-3’ 
(sense) and 
5’-cTCCATAGTTTCGTCCTAACGGACTCATCAGAAGAGCAa-3’ (antisense) 
Lower case letters indicates HindIII-/NotI restriction site overhangs, bold capital 
letters shows CEA specific antisense regions and italic capital letters indicates the 
hammerhead ribozyme core sequence. 
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The resulting ribozyme expression plasmid pTET/Rz2113 contains CEA specific 
antisense flanking regions of 7 nt on 5’ and 8 nt on 3’ ends of the 22 nt catalytic 
hammerhead ribozyme core sequence, that target it to the B3 domain of CEA.  
Additionally, the ribozyme DNA was ligated into the pRc/CMV vector which 
allows performance of an in vitro cleavage assay. 
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 Figure 3: Ribozyme expression plasmid pTET/Rz2113. 
 
 
2.2.2. In Vitro Cleavage Assay 
 
The cleavage assay was done in order to demonstrate that our ribozyme is actually 
cleaving our gene of interest (the mRNA of CEA). In order to do that a smaller in 
vitro transcripts of the full length CEA sequence was  generated and incubated it for 
different amount of time (from 0 up to 12 hours). Aliquots were taken out of the 
reaction and visualized by silver staining.  
To generated smaller in vitro transcripts, the full length CEA sequence which was 
ligated into the pBluescript II KS (+/-) vector was cut with NotI and PSTI 
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restriction enzymes. This yielded a 765 bp CEA fragment containing the 
recognition sequence for Rz2113 which was religated in a pBluescript SK (+/-) 
vector and linearized by NotI. ApaI was used to linearize the pRc/CMVRz2113 
vector. The enzymes were heat inactivated and the transcripts were refined using a 
Chroma SPIN-30+DEPC-H2O column. A run-off transcription reaction for the 
ribozyme and target RNA was carried out with T7 RNA polymerase using a 
MAXIscript Transcription Kit. After DNA digestion (DnaseI treatment) transcripts 
were refined with Chroma columns. The purified RNA products were combined 
(100 fold molar excess of ribozyme transcripts) and resuspended in a 50µl reaction 
volume containing 50mM Tris-HCl (pH 7.5) and 1mM EDTA and heated 3 minutes 
at 95°C and quick-cooled on ice. The reaction was started by addition of Mg2Cl2 (0-
20mM) following incubation at 37°C (Palfner et al). As a negative control the same 
amount of CEA RNA was incubated under the same conditions without the 
ribozyme.  
Aliquots of 10µl were removed after 0.5, 1, 2, 4, and 12 hours and the reaction was 
stopped by the addition of Ambion Loading buffer II including 40mM EDTA and 
stored at -80°C. Samples were visualized by silver staining according the 
manufacturers protocol with the exception that 2mg/l Na2S2O3 was added to the 
developing reaction to reduce background staining. 
 
2.2.3. Cell Lines and Transfection 
 
Human HT29 colon cancer cells were obtained from the American Type Culture 
Collection (ATCC) and were maintained in continuous culture at 37°C/5% CO2 
using IMEM supplemented with glutamine 1% and 10% heat-inactivated fetal 
bovine serum (FBS). Murine MC38 colon cancer cells and human CEA expressing 
MC38 cells were kindly provided by Dr. J. Shively. MC38 cells were stable 
transfected by electroporation using a eukaryotic expression vector (neomycin 
resistance gene) which contained the full length cDNA of human CEA. CEA 
expressing clones were obtained after G418 selection. CEA expression levels 
exceeded the CEA expression of HT29 cells by a factor of 2 determined by FACS 
analysis. 
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HT29 cells were transfected in a 96-well-plate using LipofectAmine. Cells at 50-
70% confluency were incubated for 5 hours with plasmid DNA mixed with 
LipofectAmine in a ratio of 1:10 (9µl LipofectAmine/1µg plasmid DNA) in serum-
free Opti-MEM medium at 37°C in 5% CO2. The transfection medium was the 
replaced with normal growth medium and 36 hours later supplemented with the 
respective drugs for selection of stable integrants. HT29 stable expressing 
tetracycline regulated CEA targeted ribozymes were generated in a two-step 
transfection protocol. In a first step, HT29 cells were transfected with 9µg of 
pUHG15-1 plasmid DNA and 1µg of pRc/CMV plasmid DNA to provide Geneticin 
(G418) resistance. After selection for stable integrants in the presence of G418 at 
0.7mg/ml individual tTA expressing clones were isolated. To test the clones for 
tTA expression and tetracycline regulation, a luciferase assay was performed.  
Clone HT29/tTA-5 demonstrating the best tetracycline regulation of luciferase 
activity was used for further transfections with the ribozyme expression plasmids. 
HT29/tTA-5 cells were then transfected with 9µg of pTET/Rz2113 mixed with 1µg 
of pZeo to provide Zeocin resistance. Clones, obtained after selection with 
0.4mg/ml Zeocin and 1µg/ml tetracycline, were screened for tetracycline regulated 
CEA expression using FACS analysis. Each clone was screened three times in 
order to get reliable results. Two clones, showing best tet-regulation of CEA 
(HT29/Rz4 and HT29/Rz4-2), and were used for further experiments. 
 
2.2.4. Luciferase Assay  
 
Luciferase refers to a family of enzymes that catalyse the oxidation of various 
substrates (e.g. luciferin), resulting in light emission. Luciferases are used in 
expression assays, where the luciferase acts as a “reporter” for the activity of any 
regulatory elements that controls its expression. 
To test the clones for tTA expression and tetracycline regulation, the cells were 
transiently transfected with pUHC13-3 plasmid DNA that contains a luciferase 
cDNA under the control of the tet-O binding site and cultured in the absence and 
presence of 1µg/ml tetracycline, respectively. For this cells were plated overnight at 
60-70% confluency in six-well plates and then transfected in Optimem with 1µg of 
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DNA per well using 7µl of LipofectAmine. After 5 hours transfection medium was 
replaced by fresh culture medium and the cells were incubated for another 36 hours. 
After incubation cells were harvested, washed, lysed in 0.25 M Tris⋅HCl (pH 7.8) 
and freeze-thawed three times. 5-20µl of the lysate was mixed thereafter with 350µl 
of 0.1 M potassium phosphate/15 mM MgCl2/5 mM ATP at pH 7.8 and assayed for 
luciferase activity using 1mM D-luciferin as a substrate. A cytomegalovirus-driven 
vector was used to control for transfection efficacy (Schulte A et al). 
 
2.2.5. Northern Analysis 
 
Total cellular RNA was isolated by using the commercially available RNA STAT-
60 method and protocol. 30µg of total RNA were mixed in RNA loading mix, 17.5 
% formaldehyde, 50 % formamide, 10 % RNA-formaldehyde loading buffer heated 
to 65°C for 10 minutes and separated by electrophoresis in 1.6 % formaldehyde-
agarose gel and then blotted onto nylon membranes. The blots were prehybridized 
in 6 x SSC, 0.5 % (w/v) SDS, 5 x Denhardt’s solution for 4 hours at 68°C and 
hybridized overnight at 68°C in hybridization solution (same composition as the 
prehybridization solution with addition of 0.01 M EDTA (pH 8.0)) containing a [α-
32P]dCTP-labeled CEA cDNA probe (541 nt PstI fragment) This probe was 
prepared by using a commercially available random primed DNA labeling kit. 
After hybridization, blots were washed once with 1 x SSC and 0.1 % SDS for 20 
minutes, once with 0.2 x SSC and 0.1 % SDS for 20 minutes at room temperature, 
and once for 20 minutes at 68°C (Fang WJ et al). Blots were then autoradiographed 
using intensifying screens at -70°C for 16 hours. To correct for variability in 
loading 18s RNA bands were used or blots were stripped and re-probed with a 
Glyceraldehyde-3 phosphate dehydrogenase (GAPDH) cDNA probe. Relative band 
intensities were measured by densitometry. 
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RNA isolation 
 
RNA was isolated from cell lines using RNA-STAT60, which is based on the single 
step method of RNA isolation developed by Chomczynsky and Sacchi 
(CHOMCZYNSKY, P. and SACCHI, N., 1987).  
Cells were grown in 15 cm tissue culture dishes to approximately 80 % confluence. 
Medium was aspirated and 1ml of RNA-STAT60 was added onto the cells. Cells 
were scraped off the plate, transferred to a microcentrifuge tube and allowed to 
incubate at room temperature for 5 minutes. 0.2ml of chloroform was added to each 
sample and vortexed for 10 seconds and incubated at room temperature for 3 
minutes. Next, a 15 minute centrifugation at 15.000g was performed at 4°C. After 
centrifugation the RNA-containing aqueous phase was transferred to a fresh 
microcentrifuge tube. To precipitate the RNA, 0.5 ml of isopropyl alcohol was 
added, vortexed shortly, incubated at room temperature for 5 minutes and 
centrifuged at 15.000g for 10 minutes. The visible pellet (RNA) was washed with 
80 % ethanol and centrifuged for 5 minutes at 7.500g. Supernatant was discarded 
and dry pellet was dissolved in 20-50µl of DEPC-treated water and stored at -80°C. 
RNA concentration was determined via UV spectrophotometry. 
 
Preparation of radioactive probes 
 
CEA probe 
 
The CEA probe was prepared from a pBluescript II KS vector, which contained full 
length cDNA of CEA. The plasmid was kindly provided by M. Neumaier 
University of Hamburg. A fragment of 541 nt was isolated by restriction enzyme 
digestion with PSTI followed by separation on a 1 % agarose gel. The DNA 
fragment was then cut out of the gel and extracted from the gel with a commercially 
available kit (QiaQUICK gel extraction kit). 
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Agarose gel extraction 
 
Extraction of DNA fragments from an agarose gel was performed using the 
QiaQUICK gel extraction kit. DNA was sliced out from the gel and weighed. 3 
volumes of a provided solubilizing buffer were added per 1 volume of gel. Next, a 
10 minutes incubation at 50°C was carried out. Afterwards samples were 
centrifuged and the supernatant was discarded. The pellets were washed once with 
a high salt buffer to remove residual agarose and twice with ethanol containing 
buffer to remove salt contaminants. Residual ethanol was removed by air drying. 
DNA was eluted by resuspending the pellet in water. The concentration of the 
purified DNA was measured by UV spectrophotometry. 
 
GAPDH probe 
 
GAPDH cDNA probes were used to standardize for RNA loading in Northern 
analyses. A 1.1 kb fragment for GAPDH cDNA was purchased from Clonetech. 
 
CEA and GAPDH probes were generated by random prime labeling. 
 
Random prime labeling of cDNA 
 
The commercially available labeling system was used to generate radioactive 
labeled probes from cDNA. 50ng of cDNA was brought to a final volume of 45µl 
and boiled for 5 minutes (denaturation of cDNA) and then put on ice for 2 minutes. 
Next, the cDNA was added to a reaction mix containing dNTP, random primers and 
Klenow enzyme. 5µl of α-32P-dCTP was added to the reaction, which was then 
incubated at 37°C for 30 minutes. The unincorporated nucleotides were removed by 
Sephacryl HR resin columns. Activity was measured in a scintillation counter. 
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2.2.6. Fluorescence Activated Cell Sorting (FACS) 
 
FACS analysis is the measurement of cellular properties as they are passing through 
a laser. The emitted light from the excitated fluorochrome (target) is registered and 
quantified on a graphic. 
For the FACS analysis cells were detached using 0.02 % EDTA in PBS, washed 
with ice cold PBS containing 7.5mM sodium azide and 5 x 105 cells were incubated 
with 2µg of anti-CEA antibody for one hour at 4°C. The cells were then washed 
three times with ice cold PBS and then incubated for an additional 30 minutes with 
1:100 diluted DTAF-conjugated goat anti-mouse IgG + IgM antibody in the dark 
and at 4°C. After two final washings, cells were resuspended in 300 µl of PBS and 
fixed by the addition of 100µl of 4 % paraformaldehyde. The mean values of the 
fluorescence intensity were determined by FACS analysis. Unlabeled cells and cells 
labeled only with the secondary antibody served as a negative control. 
 
2.2.7. Western Blot Analysis 
 
The western blot is a method to detect and quantify proteins from cells or tissues. 
Proteins are blotted onto a membrane and visualized by antibodies which bind to 
their target.  
Cells were grown to approximately 80 % confluency and harvested by scraping 
them in ice cold PBS on ice. They were pelleted by centrifuging at 100g for 2 
minutes and lysed in lysis buffer. Cells were incubated on ice for 10 minutes, 
vortexed briefly and spun down at 15000 g and 4 °C for 10 minutes. The 
supernatant, containing the protein, was transferred to a clean 1.5ml Eppendorf tube 
and protein levels were measured by Bradford assay. 
Equal amount of total protein (40µg), mixed in a 1:3 ratio in 3 x loading buffer, 
were loaded into pre-cast 4-20 % gradient Tris-glycine polyacrylamide gels and 
gels were run at 130 V in Running buffer.  
Gels were transferred onto Immobilon-P nylon membranes for 3 hours at 150 mA 
per gel, the membranes were dried overnight, rehydrated, and blocked for 1 hour in 
PBST and 5 % nonfat dry milk. 
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Membranes were probed with a 1:500 diluted monoclonal mouse antibody to CEA 
for two hours at room temperature. Membranes were washed 4 times in PBST 5 
min. each, followed by incubation with 1:5000 diluted rabbit anti-mouse IgG 
antibody conjugated to horseradish peroxidase. Immunoreactive bands were 
visualized by enhanced chemiluminescence 
 
2.2.8. Aggregation Assay 
 
To determine aggregate formation a modified soft agar assay described below 
(2.2.14) was performed. Tumor cells were incubated under continuous agitation in 
complete medium and fixed after the incubation time in a layer of soft agar. 
Therefore, single cell suspensions of HT29 cells were prepared by drawing cells 
through a 30G x “needle. Cells were kept in suspension for 20 minutes in a rotating 
advice at 37°C to allow aggregation. After incubation period cells were seeded into 
liquid agar at 42°C. The soft agar solidified an image analyzer was used to 
determine the number of aggregates larger than 60 µm in diameter which 
corresponds to a cluster of at least 10 cells. 
 
2.2.9. Tumor/Endothelial Cell Adhesion Assay 
 
This assay was performed to determine the effect of endogenous CEA on the 
binding of HT29 cells to endothelial cells (HUVEC). 
 HT29/Rz4 cells and HUVEC cells were labeled with different commercially 
available fluorescent dyes (red and green) and recultivated over night to recover the 
cells from the labeling procedure. The following day single cell suspension of cells 
were prepared and kept in suspension for 0, 20 minutes, 1 and 2 hours in an rotating 
advice at 37°C to allow adhesion. Adhesion of HT29 cells to HUVEC cells were 
determined by running cell suspension after different time points through a flow 
cytometry and counting red and green fluorescent cell clumps. 
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2.2.10. cDNA Microarray 
 
The principle of a microarray is that mRNA from a given cell line or tissue is used 
to generate a labeled sample, which is hybridized in parallel to a large number of 
DNA sequences immobilized on a solid surface.  
For cDNA microarray analysis, the “Atlas™ Human Cancer cDNA Expression 
Array” was used which covers 588 cancer related genes spotted on positively 
charged nylon membranes and arranged in 13 functional groups (cell cycle/growth 
regulators, intermediate filament markers, apoptosis, oncogenes/tumor suppressors, 
DNA damage response/repair and recombination, cell fate and development, 
receptors, cell adhesion and motility, angiogenesis, invasion regulators, cell-cell 
interactions, Rho family and small GTPases, growth factors and cytokines). 
Plasmid and bacteriophage DNAs are included as negative controls to confirm 
specificity, along with several housekeeping cDNAs as positive controls. The 
microarray analysis was performed according to the manufactures guidelines. 
HT29/Rz4 cells were cultivated in culture medium. 12, 24, and 48 hours before 
harvesting equivalent amounts of cells were distributed in 6 culture flask and 1 
µg/ml tetracycline was added in 3 flask to block ribozyme expression. Cells were 
detached by 0.02 % EDTA/PBS and cells with and without tetracycline treatment 
were pooled. The cells in all flasks were at comparable levels of confluence at the 
time of harvesting. HT29/tTA5 cells were treated in the same way and served as a 
control. 
RNA was extracted according to the manufacturers protocol, which is a 
phenol:chloroform based method, followed by a 30 minutes incubation at 37 °C 
with DNAse I. A Northern Blot for CEA was performed to confirm intact RNA and 
regulation of CEA levels before experiment were continued. 
For cDNA synthesis 50µg total RNA was used which was converted to 32P-labeled 
first strand cDNA by means of SuperScriptII reverse transcriptase. Unincorporated 
nucleotides were removed by CHROMA SPIN-200 column chromatography. The 
first two fractions with highest activity were pooled. Equivalent amounts of cpm 
were used to minimize loading differences. Pre-hybridization of the membrane was 
done for 30 minutes with continuous agitation at 68°C in ExpressHyb 
supplemented with 200µg/ml salmon sperm DNA. After pre-hybridization heat 
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denaturated 32P-labeled probe was added. Hybridization was performed over night 
at 68 °C with continuous agitation. The following day the membrane was washed 
four times with 200 ml or pre-warmed Wash Solution 1 for 30 minutes at 68°C with 
continuous agitation. After washing the membrane four times with Wash Solution 
1, membrane was washed one time with Wash Solution 2 for 30 minutes at 68°C 
again with continuous agitation. A final wash of 5 minutes with 2 x SSC was done 
at room temperature. 
The hybridization was analyzed by autoradiography followed by phosphoimager 
analysis for quantification.  
 
2.2.11. Cell Cycle Analysis 
 
Cell cycle analysis was performed by the Vindelov staining method (Vindelov et al 
1983), which is a method based on detergent lysis of cell membranes and 
production of stained nuclei in monodisperse suspension in a single step. 
Tetracycline treated and untreated cells were harvested, 2 x 106 cells were 
resuspended in 100µl of 40mM citrate/DMSO buffer. Solution A (1800µl) was 
added to 200µl of the cell suspension in citrate buffer and the tube was inverted to 
mix the contents gently. After 10 minutes at room temperature, during which the 
tube was inverted five to six times, 1500µl solution B was added. The solutions 
were again mixed by inversion of the tube and after additional 10 minutes at room 
temperature 1500µl ice-cold solution C was added. The solutions were mixed and 
the samples were filtered through a 30µm nylon mesh into tubes wrapped in 
aluminum foil for light protection of the PI. Cell cycle analysis was performed by 
flow cytometry. 
 
2.2.12. Proliferation Assay 
 
Cell numbers were determined by a colorimetric assay, based on the cleavage of the 
tetrazolium salt WST-1 in viable cells, according to the protocol of the 
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manufacturer. Tetrazolium salts are metabolically reduced by cellular enzymes to 
highly colored end products called formazans. 
5 x 103 cells were cultured in microtiter plates (96 well plates) in a final volume of 
100µl/well culture medium and standard culture conditions. Cells were divided into 
two groups. One group being treated with 1µg/ml tetracycline per well and the 
other group without tetracycline treatment. After incubation period of 3 days 10µl 
of WST-1 reagent was added into each well and incubated for 30 minutes in a 
humidified atmosphere at 37°C. The absorbances of the samples were determined at 
450nm using ELISA microreader. A well with 100µl culture medium and 10µl 
WST-1, but without cells worked as a background control.  
A time kinetic over 3 days was also performed in the same way as described above.  
 
2.2.13. Determination of Apoptosis 
 
Apoptosis is known to be an important factor in tumor growth. Determination of 
apoptosis was performed by using a commercially available AnnexinV kit. 
AnnexinV is a calcium-dependent phospholipid binding protein, with a high 
affinity for phosphatidylserine (PS). During apoptosis, an early and ubiquitous 
event is the exposure of phosphatidylserine at the cell surface. Since necrotic cells 
are leaky enough to give access to inner membrane PS, apoptotic cells were 
differentiated from necrotic cells by simultaneous staining with Annexin V and the 
DNA stain propidium iodid. 
HT29/Rz4 cells (1 x 106), treated with and without tetracycline, were harvested, 
washed twice with 500µl cold PBS and resuspended in 100µl of propidium iodide-
AnnexinV-FITC dual staining solution as described in the manufacturers manual 
and incubated in the dark for 15 minutes at room temperature. 400µl 1 x binding 
buffer was added to cell suspension and cells were analyzed by flow cytometry. 
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2.2.14. Colony Formation Assay 
 
To determine colony formation a modified soft agar assay described previously 
(JUHL et al 1997) was performed.  
24 hours before the actual assay, cells were divided into two groups, one group 
receiving 1 µg/ml tetracycline. 5 x 103 single cells in 0.35 % agar were layered on 
top of 1ml of solidified 0.6 % agar a layer in a 35mm dish. Growth media (IMEM) 
with 10 % FBS were included in both layers. In addition 1µg/ml tetracycline was 
added into the agar of tetracycline receiving group. Colonies more than 80µm in 
diameter were counted after 0, 1, and 2 weeks of incubation time using an image 
analyzer.  
 
2.2.15. Animal Experiments 
 
4-6 weeks old Ner nude mice were obtained from the NCI (Frederick, MD). Mice 
were housed at standard temperature (22°C), humidity (50-60%) and light (light-
dark cycle 12:12 hours) environment with free access to food and water. Animals 
were kept at least three days according to the standards of good animal practice 
before use in experiments. All experiments were approved by the Ethics Committee 
for Animal Experiments, Georgetown University. 
HT29/Rz 4 cells, which were treated 24 hours before the assay with or without 
tetracycline to modulate CEA levels, were resuspended into 200µl complete 
medium and injected into the tail vein of mice. To block ribozyme expression one 
group of mice obtained doxycycline enriched food (a tetracycline analogue which is 
absorbed by the intestine). The second group obtained regular non-doxycycline 
enriched food. After 30minutes, 24 hour and 6 weeks mice were sacrificed, the lung 
were removed and embedded in paraffin. 
The numbers of metastatic lesions were visualized and quantified by cytokeratin 
(Kl-1) staining using light microscopy (10 x magnification) on all 5 different lung 
section per mice. 
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Figure 4: Schematic of animal experiment. Group B was divided into two subgroups. The first 
subgroup was injected with non-tetracycline pre-treated HT29/Rz4 cells, and the second subgroup 
was injected with HT29/Rz4 cells pre-treated with tetracycline. 
 
 
 
 
2.2.16. Immunohistochemistry 
 
Tissue slides were obtained from the Histopathology and Shared Tissue Resource 
of Georgetown University Medical Center as formalin-fixed, paraffin-embedded 
sections. 
Paraffin sections (5µm) were performed at 5 different regions of the lung. 
Immunostaining was used to identify metastatic lesions. Kl-1 anti-human 
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cytokeratin antibody which does not cross react with murine cells was applied to 
identify human epithelial cells. 
Slides were baked at 56°C over night, microwaved for 3 minutes and deparaffinized 
by xylene and stepwise passages through decreasing concentration of ethanol. 
 
• 2 x 5 minutes in xylene 
• 2 x 5 minutes in 100 % ethanol 
• 1 x 10 minutes in 100 % ethanol 
• 1 x 1 minute in 90 % ethanol 
• 1 x 1 minute in 80 % ethanol 
• 1 x 1 minute in 70 % ethanol 
• 1 x 1 minute in ddH2O 
 
Then slides were placed into a 0.3 % H2O2 solution for 20 minutes at 4°C to quence 
endogenous peroxidase, followed by a washing step of 3 times in PBS for 5 
minutes. Slides were then blocked in 1 % BSA/PBS for 15 minutes at room 
temperature and incubated with the primary antibody (Kl-1) diluted 1:250 in 1 % 
BSA/PBS for 2 hours at room temperature. After washing the slides 3 times with 
PBS for 5 minutes slides were incubated with the secondary antibody (peroxidase 
conjugated rabbit anti-mouse antibody) diluted 1:1000 in 1 % BSA/PBS for 1 hour 
at room temperature. Next, slides were washed 3 times with PBS for 5 minutes and 
incubated for 5 minutes in a diaminobenzidine (DAB) solution. Slides were 
counterstained with hematoxylin, washed in ddH2O, dehydrated and mounted in 
mounting medium. 
 
2.2.17. Phage Display 
 
The mean of a phage display is to analyze the interaction of the target protein with 
other, already known or unknown proteins. A peptide or protein is displayed on the 
surface of a phage as a fusion protein that is normally found in the phage particle. 
Phage display has been used to identify peptides that bind to receptors, substrates or 
inhibitors of enzymes, epitopes, improved antibodies, altered enzymes and cDNA 
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clones (O’NEIL, K. T. wt al, 1995). The cDNA of a human colon cancer cell line 
(LS174 T) was screened for interaction of CEA with other proteins. The cDNA 
library was prepared and kindly provided by A. Wellstein. 
 
Preparation of bacteria culture 
 
BLT 5615 (E.coli) were grown in 15 % LB media. For each experiment fresh 
bacteria culture was prepared. LB media was prepared, autoclaved and stored at 
4°C. Before use of the bacteria a little amount of bacteria was put into 6 ml of LB 
media in a 15 ml tube and incubated for 3 hour at 37 °C under continuous strong 
agitation. 
 
Phage display 
 
500ng of purified CEA was immobilized on a 6-well plate containing 2 ml of 1 x 
PBS over night at 4°C. The following day wells were washed three times with 2 ml 
of 1 x PBS. After washing, wells were blocked for 4 hours with LB media. Wells 
were washed five times with 1 x PBS after blocking with LB media. 1012 phages 
were put into each well and incubated for 20 minutes at room temperature. After 20 
minutes 2 ml of freshly prepared bacteria culture was added into each well and 
incubated for additional 10 minutes. An aliquot of10µl was taken from each well 
and used for the titration series. The rest of the phage/bacteria culture was taken out 
from each well and amplified separately over night in freshly prepared LB media at 
37°C. 
This procedure was repeated five times (round 1-5). After the last round phages 
were amplified over night and lysed for PCR. 
 
Amplification of Phages 
 
For amplification, phages were incubated over night in a 15 ml tube in 6 ml freshly 
prepared bacteria culture. Incubation was performed at 37°C under continuous 
strong agitation. After the incubation period bacterial culture with the phages were 
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centrifuged at 10.000g for 3 minutes to separate the bacteria lysate from the phage. 
The supernatant was aliquoted into fresh 2ml tubes and stored at -80°C.  
 
PCR with Phages as DNA template 
 
15µl of amplified phages were mixed with 35µl of EDTA resulting in a final 
concentration of EDTA of 10mM (pH 8). Mixture was heat inactivated for 10 
minutes at 65°C. 5µl of the mixture was put into the PCR reaction mix (see 
material part) and run for 38 cycles. 1 Cycle: 
 
1. 95°C for 60 sec. (denaturation) 
2. 37 °C for 60 sec.(annealing) 
3. 72°C for 60 sec. (extension) 
 
The final extension was applied for 5 min. and stopped by cooling down to 4°C. 
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3. RESULTS 
 
3.1. Cleavage of CEA mRNA 
 
To determine the capability of the ribozyme to cleave the mRNA of CEA the 
ribozyme was incubated in a 100-fold molar excess with the CEA mRNA for 
various time points (0.5, 1, 2, 4 and 12 hours). Already after 0.5 hour it was 
possible to detect the cleaving products of the 814 nt CEA mRNA transcript. The 
CEA mRNA transcript was completely cleaved by Rz4 in a 412 nt and a 393 nt 
long fragment after 12 hours (Figure 4). 
As a negative control, the same amount of CEA mRNA was incubated under the 
same condition without the ribozyme. The mRNA was stable and did not degrade 
during the 12 hours of incubation time. Of note, studies have been done to 
document the specificity of ribozymes. Werner, M. et al studied the effect of base 
mismatches in the substrate recognition helices of hammerhead ribozymes on 
binding and catalysis. They demonstrated that ribozymes lack already cleavage 
activity if there is a mismatch of two or more nucleotides (WERNER, M. et al 
1995).  
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Figure 5: In vitro cleavage assay to determine the activity of CEA-targeted ribozyme Rz4 
(sequence shown in the insert). A CEA transcript of 814 nt was coincubated with 100-fold 
excess of Rz4 for various time intervals. The expected cleavage products of 421 nt and 393 nt 
lenght became visible after 1 hour. As a control served CEA RNA without addition of Rz (M= 
molecular weight marker). 
 
 
 
 
 
3.2. Tetracycline Dependent Regulation of the tTA Protein 
 
A luciferase assay was done in order to determine tetracycline dependent regulation 
of gene expression in stably transfected HT29 colon cancer cell clones. 
After transient transfection of the luciferase gene inserted in the tTA binding vector 
(pUHC13-3 plasmid) we demonstrated very efficient tetracycline dependent 
regulation. Luciferase activity was measured 36 hours after transient transfection in 
the absence and presence of tetracycline. 
Figure 5 shows a luciferase assay of HT29 colon cancer cells which stable express 
the tTA expression vector and enable tetracycline regulated expression of the 
luciferase reporter gene. From various HT29/tTA clones, which demonstrated 
tetracycline dependent regulation, clone HT29/tTA-5 showed most efficient 
tetracycline dependent regulation (by a factor of 100) and was used for further 
transfection with the ribozyme plasmid. 
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Figure 6: Luciferase assay. HT29 cells expressing the tetracycline Transactivator (tTA) protein 
were transiently transfected with pUHC13-3 plasmid DNA that codes for luciferase under the 
control of the tet-O binding site. Luciferase activity was measured 36 hours after transfection in 
the absence and presence of tetracycline (1µg/ml). 
 
 
3.3. Reduction of CEA on the Protein Level 
 
After transfection of HT29/tTA-5 clone with the ribozyme cells were screened for 
tetracycline dependent CEA regulation by FACS analysis. Each clone was screened 
three times for reliable results. From two separate transfection experiments 9 out of 
a total of 70 clones, demonstrated tetracycline dependent CEA down-regulation 
ranging from 20-50 % by FACS analysis. Two out of those 9 clones showed CEA 
regulation in a tetracycline dependent manner of ~50 % on the protein level and 
were therefore chosen for further experiments. Clones were named HT29/Rz4 and 
HT29/Rz4-2 and both of them were transfected with ribozyme 4. 
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The tetracycline regulated reduction of CEA expression in HT29/Rz4 and 
HT29/Rz4-2 cells was confirmed on the protein level by FACS and Western blot 
analysis in several independent experiments.  
Figure 6 shows the results from a FACS analysis. Overall, both clones showed a 
ribozyme dependent decrease of CEA expression by approximately 50 %. Western 
blot analysis showed even a reduction of CEA by 70 % (figure 7). 
 
 
Figure 7: FACS-analysis of HT29/Rz4 cells.  
 
 
To determine the time kinetics of ribozyme activity with CEA translation (protein 
expression), a Western blot was performed measuring the CEA levels in HT29/Rz4 
clone at various time intervals after addition of tetracycline (figure 7).  
The Western blot showed antibody staining of exclusively one specific CEA band 
of Mw 180 kDa. Half of the CEA expression was reversed after 9-12 hours of 
tetracycline treatment and maximal CEA levels were seen after 24 hours. As a 
control, CEA levels were measured in HT29/Rz4 cells continuously cultured 
without tetracycline. It is shown, that these cells had consistently low levels of 
CEA. 
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Figure 8: Western blot analysis to demonstrate regulation of CEA level in HT29/Rz4 cells. 
Ribozyme expression reduced CEA levels by approximately 70% (difference between the 
first and the last time point). Addition of tetracycline inhibited ribozyme expression, and 
subsequently, restored CEA protein levels. As a control, HT29/Rz4 cells were kept in 
culture in the absence of tetracycline. 
 
 
 
 
 
3.4. Reduction of CEA on the RNA Level 
 
In accordance with the results from the FACS analysis and Western blot assay we 
performed a Northern blot to see a tetracycline dependent regulation of CEA on the 
RNA level. Figure 8 shows a Northern blot analysis with a 50 % reduction of the 
CEA RNA. As a negative control CEA-non-expressing MC38 murine colon cancer 
cells were used. MC38 cells stably transfected with a CEA expression vector were 
used as a positive control. One can see on the picture that the molecular weight of 
CEA transcript in murine cells were slightly higher than CEA mRNA in human 
HT29 cells. This is possible because of a longer poly(A)-tail in the murine cell 
CEA mRNA. 
 
 53
M C 3 8
C E A  
tra n sfe c ted
M C 3 8
w t
H T 2 9 /R z 4
- te t
H T 2 9 /R z 4
+  te t
 
Figure 9: Northern Blot analysis. 1 = MC38 murine colon cancer cell line overexpressed 
with human CEA cDNA, 2 = MC38 cells (CEA negative), 3 = ribozyme expressing 
HT29/Rz4 (-tet.) and 4 = ribozyme inhibited (+tet.) HT29/Rz4 cell line. Ribozyme 
expression reduced CEA levels by approximately 50%. 
 
 
 
3.5. CEA’s Role as an Adhesion Molecule 
 3.5.1. Involvement of CEA in Tumor-Tumor Cell Adhesion 
 
Figure 9 demonstrates that CEA contributes to aggregate formation of HT29 colon 
cancer cells. For determination of aggregate formation a modified soft agar assay 
was performed. Aggregates >40µm (cluster of at least 4 cells) and aggregates 
>60µm (clusters of at least 10 cells) were determined. A dramatic reduction of 
aggregate formation (up to approximately 70 %) of CEA reduced HT29 cells was 
observed. Tetracycline itself did not affect aggregation formation in HT29/tTA5 
wild type cells.  
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Figure 10 A: In vitro aggregation assay to determine CEA dependent aggregate formation 
of HT29 colon cancer cells. HT29/Rz4 and HT29/Rz4-2 cells were treated with or without 
tetracycline to modify CEA levels. Cells were incubated for 0 h at 37°C under continuous 
agitation and seeded in soft agar. The number and size of aggregates were determined. 
Cell clusters of 60 >µm diameters were determined. 
 
 
 
 
 
B. 
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Figure 10 B: In vitro aggregation assay to determine CEA dependent aggregate formation 
of HT29 colon cancer cells. HT29/Rz4 and HT29/Rz4-2 cells were treated with or without 
tetracycline to modify CEA levels. Cells were incubated for 2 h at 37°C under continuous 
agitation and seeded in soft agar. The number and size of aggregates were determined. Cell 
clusters of 60 >µm diameters were determined. 
3.5.2. Involvement of CEA in Tumor/Endothelial Cell Adhesion 
 
To determine the ability of HT29 cells to adhere to endothelial cells (HUVEC cells) 
we established a method to determine the adhesive function of CEA to HUVEC 
cells. We labeled each cell line with a different commercially available fluorescent 
marker. HT29 cells were labeled with a red fluorescent marker and the endothelial 
cells with a green fluorescent marker and run through an FACS analyzer to 
determine the number of red/green labeled aggregates. Regardless of CEA levels 
tumor cells increasingly bound to endothelial cells.  
However, when endothelial cells were treated with IFN-γ for 24 hours before the 
actual adhesion assay there was a decrease of adhesion over time in those cells 
which had normal CEA levels (cells treated wit tetracycline). CEA HT29 reduced 
cells showed increased endothelial cell binding (figure 11). In the control group 
tetracycline itself did not have any effect on adhesion to endothelial cells. 
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Figure 11 A: Adhesion of HT29/Rz4 cells to HUVEC cells treated with 1000 U of Interefron-γ. 
Each cell line was labeled with a fluorescent marker (red or green). HT29/Rz4 cells were treated 
with or without tetracycline and incubated for 0 to 2 hours with HUVEC cells at 37°C under 
continuous agitation. Cell clusters (red and green) were determined with a FACS analyzer. A)
HT29/Rz4 with HUVEC cells, without Interefron-γ treatment  
 56
B. 
3500 
3000 
N
um
be
r o
f A
gg
re
ga
te
s 
2500 
2000 - Tet.
+ Tet.1500 
1000 
500 
0 
2 h 0 h 0.5 h 1 h
Time (h)
 
C. 
3000 
2500 
N
um
be
r o
f A
gg
re
ga
te
s 
2000 
- Tet.
1500 + Tet.
1000 
500 
0 
0 h 0.5 h 1 h 2 h
Time (h)
 
 Figure 11 B + C: Adhesion of HT29/Rz4 cells to HUVEC cells treated with 1000 U of 
Interefron-γ. Each cell line was labeled with a fluorescent marker (red or green). HT29/Rz4 cells 
were treated with or without tetracycline and incubated for 0 to 2 hours with HUVEC cells at 
37°C under continuous agitation. Cell clusters (red and green) were determined with a FACS 
analyzer. B) HT29/Rz4 with HUVEC cells treated with Interefron-γ. C) Adhesion of HT29/tTA-
5 cells (control cells without ribozyme) to HUVEC cells treated with 1000 U of Interefron-γ.  
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3.6. CEA Dependent Gene Expression 
 
The gene expression of HT29 cells were studied using the cDNA gene expression 
array. The mRNA levels of HT29/Rz4 cells were analyzed comparing ribozyme 
expressing cells (cells without tetracycline treatment) and ribozyme depressed cells 
(cells treated with tetracycline) (figure12).  
 
 
 
 
 
HT29-Rz4 -tetracyclin
(Rz on = CEA down)
HT29-Rz4 +tetracyclin
(Rz off = CEA normal)
Figure 12: Microarray with HT29/Rz4 cells. Cells were incubated 24 hours before RNA 
extraction with or without tetracycline. Two seperated microarrays were performed (one with 
cells treated with tetracycline and one array with cells without tetracycline treatment). 
 
To exclude potential influence of tetracycline on gene expression, we analyzed the 
wild type cells treated with and without tetracycline in parallel. Signals with an 
intensity >1000 were regarded as reliable signals.  
Reliable signals were available for 273 out of 588 genes. The signal intensity on 
each membrane was adjusted to houskeeping genes. A shift of gene expression by a 
factor of 1.5 was regarded as significant. In that case 134 genes were affected by 
CEA. The change of CEA level resulted in a different gene expression in virtually 
all group of genes, including: cell cycle, cell fate development regulators, growth 
factors/cytokines, Rho family, invasion regulators, angiogenesis regulators, cell 
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adhesion/motility and invasion, receptors, DNA damage response, apoptosis and 
the intermediate filament markers. Table 1 gives the detailed data for genes which 
we which showed a >2-fold CEA dependent difference of expression. These effects 
were not seen in the wild type cells when tetracycline alone was added. 
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 - Tet. + Tet. - Tet./+Tet. 
 
Cell cycle/ proliferation 
   
Cell divisio protein kinase 4 3420 13572 0.25 
Cell division protein kinase 5 2524 9372 0.27 
E2F-1 pRBbp 1000 2923 0.34 
Cyclin A 23107 12858 1.80 
C-myc bp 2591 1000 2.59 
ERK6 15588 5962 2.61 
PIN1 3315 1000 3.32 
s/t-PK PCTAIRE-3 3426 1000 3.42 
Cyclin D3 5210 1000 5.21 
s/t-PK PCTAIRE-1    
 
Intermediate filaments 
   
Cytokeratin 2E 17292 2426 7.13 
 
Apoptosis 
   
TRAF6 3163 1513 2.09 
CRAF1 3273 1154 2.84 
casp9 prec 2970 1000 2.97 
PDCD2 6206 1000 6.21 
 
  Oncogenes/tumorsuppresors 
   
MDMX 2841 1000 2.84 
STAT5B 2840 1000 2.84 
 
DNA damage and repair
   
DNA repair protein XRCC1 6110 1463 4.18 
 
Cell fate 
   
smoothened 2821 1000 2.82 
dishevelled homo. 10418 3179 3.28 
dishevelled (DVL)+DVL3 5322 1296 4.11 
Notch4 4432 1000 4.43 
WNT-8B 4635 1000 4.64 
Table 1: Microarray. List of genes and gene groups which were affected by CEA. 
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Jagged2 6633 1000 6.63 
 
Receptors 
   
RARalpha 1 + PML-RAR protein 1495 3865 0.39 
RARgamma 6414 3264 1.97 
HER3 2876 1000 2.88 
FAU 46754 8609 5.43 
IGFBP6 9451 1000 9.45 
 
Invasion regulators 
   
MMP-11; stromelysin-3 2881 1339 2.15 
metastasis-associated MTA1 2969 1136 2.61 
platelet basic protein precursor PBP 2620 1000 2.62 
TIMP-2 5377 1144 4.70 
MMP-17 6443 1000 6.44 
Emmprin 32669 1000 32.67 
 
Cell adhesion 
   
laminin 3kDA receptor 29457 13110 2.25 
netrin-2 3853 1000 3.85 
LAR 4400 1000 4.40 
integrin a3 chain 5039 1000 5.04 
 
Angiogenesis 
   
STK-1 3778 962 3.93 
tie-1 precursor 4959 797 6.22 
Cystein-rich FGFR 2552 1219 2.09 
 
    Rho family/small GTPases 
   
Rho GDP-dissociating inhibitor 1 70418 210956 0.33 
rhoB 10829 3355 3.23 
  
   Growth factors/cytokines 
   
IFN gamma inducible chem IP-10 1000 5076 0.17 
PDGF A-chain 1371 4488 0.31 
IL-10 1175 2665 0.44 
IL-7 2518 1093 2.30 
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MIF 48530 20330 2.39 
Macrophage stimulating protein MST-1 2786 1000 2.79 
VEGF 3202 1000 3.20 
pre IL-1 3283 1000 3.28 
IL-12 (NKSF p40) 3348 1000 3.35 
Metallothionein-III 7392 2127 3.48 
hepatoma der.GF 4116 1000 4.12 
KROX24 37616 6800 5.53 
Kidney EGF precursor 7507 1000 7.51 
NT-4 (NT-5) + NT-6 4683 616 7.60 
Endothelin ET2 10886 1000 10.89 
 
 
 
 
Out of all gene groups we focused on two, the cell cycle/proliferation and the 
apoptosis gene group, because an imbalance in those two pathways is known to 
affect tumor growth. When HT29/Rz4 cells were treated with tetracycline 
(ribozyme inhibition), CEA seemed to affect the cell cycle gene expression in an bi-
directional and balanced fashion, whereas the apoptotic genes were shifted in one 
direction (figure 13). 9 out of 10 apoptotic genes were down-regulated. 
Tetracycline did not affect the expression of these genes, as determined in parallel 
experiments. 
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Figure 13: Correlation of the gene expression of HT29/Rz4 cells in relation to CEA 
expression. A) genes belonging to the cell cycle/proliferation group and B) genes belonging to 
the apoptotic genes group. Indicated are genes which showed a 1.5-fold CEA dependent 
difference of expression. 
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3.7. Analysis of the Cell Cycle 
 
We saw a bi-directional and balanced shift of the genes on the cDNA array, 
belonging to the ‘cell cycle and proliferation gene group’. To see if these changes 
on the microarray had an effect in vitro, we analyzed the influence of CEA on the 
cell cycle using the Vindelov method. Both clones, HT29/Rz4 and HT29/Rz4-2 
were used to determine the influence of CEA on the cell cycle.  
Differences in CEA levels did not affect the cell cycle in HT29 colon cancer cells. 
Both clones did not demonstrate differences in the cell cycle (Figure 14). 
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Figure 14 A + B: Cell cycle assay with HT29/Rz4 cells measured after A) 0h and B) 12 
h. There was no significant effect of CEA on cell cycle of HT29/Rz4 cells.  
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3.8. Influence of CEA on Proliferation of HT29 Cells 
 
Cell numbers were determined at different time points by a colorimetric assay, 
based on the cleavage of the tetrazolium salt WST-1 in viable cells. CEA did not 
affect the proliferation rate of HT29 cells in both clonal cell lines. There was no 
difference in proliferation at any time point (figure 15). 
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Figure 15 A: Proliferation assay with control cells HT29/tTA-5 (cells without 
ribozyme). 
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 Figure 15 B+C: Proliferation assay with HT29/Rz4 and HT29/Rz4-2 cells. CEA did not 
affect the proliferation rate of HT29 cells. B) HT29/Rz4 C) HT29/Rz4-2  
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3.9. Protection of CEA Against Apoptosis 
 
Because of the fact, that the cDNA array demonstrated a shift in the apoptotic 
genes, the apoptotic rate of cultured HT29/Rz4 cells with low and normal CEA 
levels were determined by using the AnnexinV/propidium iodid staining method. 
Initially, the apoptotic rates of HT29/Rz4 cells 24 hours after tetracycline treatment 
in semiconfluent growing cells were analyzed. When HT29/Rz4 cells were grown 
to a semiconfluent stage, cells with normal CEA levels (tetracycline treated cells) 
had a slightly higher apoptotic rate than the cells with reduced CEA levels (cells 
without tetracycline treatment) (Figure 16 A). With clone HT29/Rz4-2 there was no 
difference between cells with normal CEA levels, and cells with reduced CEA 
levels. 
However, under confluent conditions the apoptotic rate in CEA reduced cells 
increased, whereas tetracycline treated cells (normal CEA levels) were not affected 
(figure 16 B). We were able to confirm these results also in HT29 IV 2 cells, with 
virtually the same results (figure 16 B). 
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 Figure 16: Analysis of the apoptotic rate of HT29/Rz4 and HT29/Rz4-2 cells under A)
semiconfluent and B) confluent growing conditions. Cells, which were stained positively for 
both, Annexin V and propidium iodid, were measured  
 
 
 
To see if CEA is able to protect the cells also under different conditions, we studied 
the protective effect of CEA against different apoptotic stimuli including UV light, 
IFN-γ and 5-FU. Regarding to HT29/Rz4 cells exposed to 200 J UV light, CEA 
seemed to protect cells from undergoing apoptosis. Cells with decreased CEA 
levels (cells not treated with tetracycline) had a significant elevated apoptotic rate 
compared to the cells with normal CEA levels (cells treated with tetracycline) 
(p<0.05) (figure17). 
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Figure 17: Analysis of the apoptotic rate of HT29/Rz4 cells treated with 200 J of UV-light. 
Apoptosis was measured 24 hours after UV-light treatment. Cells, which were stained 
positively for both, Annexin V and propidium iodid, were measured. As a control we used 
HT29/tTA5 cells (cells without ribozyme). 
 
 
 
 
 
Also, when HT29/Rz4 cells were treated with 25 units/ml of IFN-γ cells increased 
their apoptotic rate 2.5-fold in CEA down-regulated cells but had no significant 
impact on the apoptotic rate of cells with normal CEA levels (Figure 18 A). 
Finally, when HT29/Rz4 cells were treated 24 hours before the assay with 50 µM 
5-FU cells with normal CEA levels were protected from undergoing apoptosis, 
whereas the apoptotic rate increased 2.8-fold in the CEA down-regulated cells 
(Figure 18 B). 
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 Figure 18: Annexin V-PI staining with HT29/Rz4 cells. A) HT29/Rz4 cells that were
treated 48 hours with 25 U/ml IFN-γ. B) HT29/Rz4 cells that were treated 48 hours with 
50µM/ml 5-FU.  racycline alone did not affect the apoptotic rate in the wild type cells and had no 
uence on the apoptotic rate when cells were treated with UV light, IFN-γ, or 5-
. 
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3.10. Colony Formation of HT29 Cells 
 
Because we did not see a difference in the proliferation rate between the 
tetracycline treated and non-tetracycline treated cells within 72 hours we wanted to 
determine whether CEA’s antiapoptotic function has a long term effect on tumor 
cell growth. For that purpose we used a soft agar colony formation assay to 
determine the growth of HT29/Rz4 and HT29/Rz4-2 cells in relation to CEA over a 
period of 2 weeks. We found that, in both clones, cells with normal CEA levels 
(cells treated with tetracycline) developed 30 to 50 % higher colony numbers 
compared to cells with reduced CEA levels (cells not treated with 
tetracycline)(figure 19). 
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Figure 19: Colony formation assay. HT29 cells were seeded as single cells into soft 
agar. Number of colonies (>80µm in diamter) were counted after two weeks. As a 
control we used HT29/tTA 5 cells (cells without ribozyme). 
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3.11. CEA Dependent Tumor Cell Seeding and Growth in Vivo 
 
We demonstrated that CEA is not only involved in aggregate formation, but also 
protects against apoptosis and thus, promotes colony formation in HT29 cells in 
vitro. To see if those effects in vitro has any influence on the tumor growth, in vivo 
studies were performed by tail vein injection of HT29/Rz4 cells, pretreated and 
untreated with tetracycline, in nude mice. 
To detect and quantify the tumor cells or eventually metastatic lesions in the lung 
we performed an anti-human cytokeratin staining. One hour after cell injection we 
sacrificed the first group of mice. This was done in order to see if CEA is involved 
in the attachment of HT29 cells to the endothelium of the capillary system. After 24 
hours the second groups of mice were sacrificed. This was done in order to see how 
many tumor cells actually survived and attached to the organ, because it is known 
that over 99 % of cells which are injected into the bloodstream are removed within 
hours. After six weeks the last groups of mice were sacrificed to determine how 
many metastases developed.  
One hour after tumor cell injection 230 ± 20 single cells and small cell clusters per 
slide were detected in mice receiving tetracycline in contrast to 235 ± 29 cells/cell 
clusters per slide in the untreated mice. After 24 hours only 3 ± 2 tumor cells per 
slide were found in the tetracycline treated group, but non in the untreated group. 
However, after 6 weeks all five mice of the tetracycline treated group showed 
metastatic lesions (14.5 ± 4.6 lesions per mouse) whereas in the untreated group 
only one of five mice had one metastatic lesion (0.2 ± 0.2 lesions per mouse) 
(figure 20).  
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Figure 20: In vivo experiment with HT29/Rz4 cells. Cells were injected into the tailvein of nude 
mice. After six weeks mice were sacrificed and metastatic lesions were detected 
immunohistochemically. Mice which received tetracycline enriched food had more metastatic 
lesions than mice without tetracycline treatment. 
 
As a control we injected wild type cells into the mice. Irrespective of tetracycline 
treatment there was no difference between the tetracycline untreated and 
tetracycline treated group. 
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3.12. Interaction of CEA With Other Proteins 
 
To discover interaction between CEA and other proteins, especially those which are 
involved in the signal transduction cascade (e.g. proteins belonging to the apoptosis 
regulating cascade), we performed a phage display study by using the cDNA library 
of a human colon cancer cell line (LS174T). CEA was immobilized on a 6-well 
plate. Phages which bound to CEA were amplified and used for the next round. 
Figure 21 shows the binding of the phages to CEA after each round. 
 
1. 2. 3. 4. 5.Marker
 
Figure 21: Round 1 – 5 of a Phage display. CEA was immobilized using 6-Well 
plates. The cDNA library of a human colon cancer cell line (LST174) was 
screened. 
 
 
 
 
The meaning of each round was to get rid of unspecific binding. After the fifth 
round 40 clones were selected and amplified. Clones were purified and a PCR was 
run for each clone in order to identify if the clones had an insert or not. The PCR 
product was run on an agarose gel. Out of 40 clones we selected 12 clones, which 
contained a cDNA fragment and gave a positive PCR signal (figure 22). 
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100kb marker 
 
Figure 22: PCR of selected clones from the phage display. 
 
 
Some of these 12 clones coded for the same protein, resulting in 8 clones coding for 
different proteins. 
For each clone a binding assay was performed in parallel to a control protein (as a 
negative control we used LB) to see if binding of phages to CEA is specific or 
unspecific. For each clone the binding assay was repeated three times. Figure 23 
shows an example of a binding assay.  
 
 
 
 
 
 
 
 
 75
control CEA 
 
Figure 23: Titration series with clone 5:14. As a control we used LB. Clone 5:14 
shows specific binding to CEA, demonstrated by the number of plaques shown on the 
agar plates. No binding was seen with the control plate. 
 
 
 
In addition, in order to identify these proteins, a PCR was performed from these 
clones and run on a gel. The insert (or product from the PCR) was cut out of the gel 
and purified for sequencing. Table 2 gives a list of proteins we could identify after 
sequencing. 
 
 
  Table 2: Selected clones from phage display. Clone # Corresponding protein 
5:5 Homo sapiens, CGI-120 protein 
5:6 Homo sapiens, similar to ribosomal protein L5 
5:8 Homo sapiens histone deacetylase 2 (HDAC 2) 
5:11 Homo sapiens, clone IMAGE: 3611719 
5:14 Homo sapiens, ribosomal protein L24 
5:19 Homo sapiens, nuclear phosphoprotein p130 
5:28 Homo sapiens clone RP11-12N15 
5:38 Homo sapiens chromosome 10 clone RP11-
302K17 
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4. DISCUSSION 
 
The aim of this study was to elucidate the pathophysiological function of CEA in 
the pathway of metastasis. Because of the fact that CEA overexpression is one of 
the most common events in the development of adenocarcinoma, it is interesting to 
know, if CEA is also involved somehow in the pathway of metastasis.  
To analyze the function of CEA, specific CEA-targeted hammerhead ribozymes 
were designed and expressed under the control of the tet-off system. Compared to 
other approaches this has three major advantages: First, because of the high 
specificity of ribozyme molecules (UHLENBECK, O. et al 1995) it is able to target 
exclusively the gene of interest (CEA) and inhibit the translation of the mRNA to 
its actual protein, resulting in a specific inhibition of endogenous CEA expression. 
Secondly, by using the tet-off promoter system the CEA levels within identical 
cancer cell clones can be regulated. And third, by using the tet-off system it enables 
a comprehensive analysis of CEA-mediated effects within an intact 
pathophysiological cellular context. 
CEA was first described in 1965 (FREEDMAN, S. O. et al, 1965) and is the oldest 
known tumor-associated antigen. Numerous clinical studies demonstrate that CEA 
level correlates with the clinical outcome of colorectal (BRÜNNER, N. et al 1998), 
gastric (HIOKI, K. et al 1994), lung (ESTAPE, J. et al 1998) and breast cancer 
(SEIDEL, D. et al 1999). 
Since CEA has been known already from the mid sixties a lot of different 
hypothesis about the function of CEA has been proposed. C.P. Stanner’s lab 
suggested CEA functioning as an intercellular adhesion molecule (BENCHIMOL et 
al, 1989). In their study they demonstrated that CEA mediated Ca2+-independent, 
homotypic aggregation of cultured human colon adenomacarcinoma cells (LS-180). 
This could result in a greater surviving chance to form metastasis, since cell 
aggregates better survive in the blood stream than single cells. GRIFFIN, T. W. et 
al. studied the adherence of cell lines to microtiter wells coated with CEA and well 
described adhesive molecules (like laminin, collagen and fibronectin). He showed 
that the CEA positive cell line LoVo and the CEA devoid cell line H-Meso-1 did 
not differ in adherence to the extracellular matrix proteins laminin, collagen and 
fibronectin, whereas LoVo cells adhered to CEA in a specific manner, while H-
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Meso-1 showed no adhesion to CEA (GRIFFIN, T. W. et al 1991). However, P.-L. 
Lollini performed also some adhesion studies on CEA and found the opposite result 
using a human rhabdomyosarcoma cell line (P.-L. LOLLINI et al 1996). They 
demonstrated that at least for cells not metastatic to the liver CEA could interfere 
with the intercellular adhesion and therefore acts as an anti-metastatic molecule. 
They concluded that from the fact that the impairment of metastatic potential 
correlated with a reduction in homotypic adhesion properties of these cells. These 
conflicting data suggest that the function of CEA depends in part on its interaction 
with other membrane molecules and might be also tissue type dependent. However, 
so far studies about the adhesive function of CEA have only been done in cells 
which express CEA at high density or with cells which have been transfected with a 
CEA expression vector. The adhesive function has never been demonstrated in 
human colon cancer cells which show moderate or low CEA levels such as HT29 
cells. In addition, so far no one was able to give proof that the adhesive function of 
CEA plays any role under physiological in vivo conditions at all.  
By using the tet-off system we were able to analyze the impact of physiological 
CEA levels on tumor cell aggregation. We were able to regulate the CEA levels 
within HT29/Rz4 and HT29/Rz4-2 cell clones by treating them with or without 
tetracycline. Ribozyme mediated reduction of CEA levels by 50 % resulted in a 70 
% decrease in cellular aggregate formation of HT29 cells. By treating the cells with 
tetracycline we could completely reverse the ribozyme effect. Tetracycline itself 
did not affect aggregate formation in HT29 cells.  
We could demonstrate that the aggregate formation is dependent on the density of 
CEA molecules. However, in addition to that it is possible that the adhesive 
function of CEA is also tissue type dependent and that the intercellular binding 
depends not only on the CEA density, but would also include the interaction 
between CEA and other molecules. Renkonen and his group demonstrated that 
CEA is also expressed on human umbilical vein endothelial cells (HUVEC) by 
using immunohistochemistry (RENKONEN, R. et al 1994). They also 
demonstrated that CEA expression on cultured endothelial cells could be enhanced 
by TNF-α or IFN-γ. We hypothesized, that if CEA functions as a homophilic 
adhesion molecule, meaning that CEA binds to CEA, we could probably expect 
binding of CEA expressing cells to HUVEC cells. We labeled HT29/Rz4 cells with 
a red and HUVEC cells with a green fluorescent marker and performed an adhesion 
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assay. The results showed, that overall there was an increase of binding of 
HT29/Rz4 cell to HUVEC cells over time, but surprisingly binding was not 
dependent on CEA levels in HT29 cells. There was no difference between CEA-
depleted cells and cells with normal CEA levels. Maybe the density of CEA on 
HUVEC cells is too low, or the difference between normal CEA and low CEA 
levels in the HT29 cells were not enough to cause a difference. The resulting step 
was to treat the HUVEC cells with IFN-γ to enhance CEA expression. After 
treating the HUVEC cells for 24 hours with IFN-γ we repeated the adhesion assay. 
The resulting data were surprising. HT29/Rz4 cells with low CEA levels adhered 
more to HUVEC cells than the HT29/Rz4 cells with normal CEA levels. This 
experiment was repeated several times with virtually the same results, whereas in 
the wild type showed no difference between tetracycline treated and untreated cells. 
These results could confirm the hypothesis, that binding of HT29 cells is not only 
dependent on the density of CEA on the cell surface (like that would be the case in 
homophilic binding CEA to CEA binding), but is also very much dependent on the 
interaction of CEA to other molecules. However, these data are not fully 
conclusive. We don’t know the possible effects IFN-γ has on HUVEC cells, in 
addition to enhancement of CEA expression. It is very likely, that IFN-γ affects 
HUVEC cells in many different ways. In addition to the enhancement of CEA 
expression, there are most likely also many other cell surface molecules affected by 
IFN-γ. These cell surface molecules might be up-, or down-regulated as a result to 
IFN-γ treatment. In any case, these changes affect their properties to interact with 
CEA. 
 
CEA has also been implicated as a heterophilic intercellular binding molecule that 
mediates the colonization of liver and lung by colon cancer cells. Jessup, J.M. and 
his group transfected CEA into a poorly differentiated human colorectal cancer cell 
line MIP-101 and found out that the clones which expressed high levels of CEA 
were tumorigenic when injected subcutaneously into nude mice compared to the 
parent cell. They also had an increased incidence of hepatic tumors when injected 
intrasplenic into nude mice. In addition, they observed strong CEA staining in 
Kupffer cells in the normal liver adjacent to the CEA producing tumors. (JESSUP, 
J.M., et al 1995). 
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Further studies suggest that CEA might increase the metastatic capability of cancer 
cells by inducing paracrine effects on normal cells. It has been found that binding 
of CEA to Kupffer cells induces the release of various cytokines including Il-6, 
TNF-α, Il-1α and Il-1β (EDMINSTON, K. H., 1997). These cytokines are known 
to affect the microenvironment by enhancement of the expression of different 
molecules (for example different adhesion molecules) and making the 
microenvironment therefore more suitable for tumor cells. This interaction of CEA 
to Kupffer cells is believed to happen through binding to hnRNP M4, a recently 
described receptor of CEA (BAJENOVA, O. V et al, 2001). 
 
To identify genes that are potentially affected by CEA, we screened for CEA-
mediated molecular effects by performing a cDNA microarray, which covers 588 
cancer related genes arranged in 13 functional groups.  
So far microarrays have been used to investigate problems in cell biology in various 
ways. At one end, single changes in gene expression, that might be the key to a 
given phenotype or its alteration, can be discovered. At the other end, an overall 
pattern of gene expression can be studied with cDNA microarrays.  
Our intention was not to look for single genes, which might affect tumorigenecity 
of HT29 cells, but to get an overall idea if changes in gene expression are related to 
CEA.  
Our finding was surprising. 273 genes out of 588 generated reliable signal and were 
evaluated for the effect of CEA on their expression level. A sensitive parameter for 
evaluating differences in gene expression is the “fold-change sensitivity”. The 
“fold-change sensitivity” is the ability of hybridization arrays to reliably determine 
a certain magnitude difference in gene expression. The claimed fold-change 
sensitivity for radioactivity based methods varies from 1.5- to 0.66 fold 
(FREEMAN, W. M, et al, 2000).  
Using a 1.5-fold change in gene expression as a cutoff approximately half of the 
273 genes, which gave reliable signals, changed their expression level when levels 
of CEA were modified. When using a 2-fold change in gene expression as a cutoff, 
differences in CEA dependent gene expression was found in 46 genes. Even when 
using a 2-fold change in gene expression as a cutoff the CEA dependent gene 
expression was affecting virtually all gene groups. As examples for genes affected 
by CEA: CDPK4 and 5, belonging to the cell cycle group, Jagged2, belonging to 
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the fate development regulators, Interleukin12 and IFN-inducible chemokine IP-10, 
belonging to the growth factors/cytokine, rhoB, belonging to the Rho family, MMp-
17 and Emmprin, belonging to the invasion regulators, VEGFbeta, belonging to the 
angiogenesis regulator, laminin-3kDA receptor, belonging to the cell 
adhesion/motility and invasion group, IGFBP6, belonging to the receptor group, 
PDCD2, belonging to the apoptosis group and cytokeratin 2E, belonging to the 
intermediate filament markers. 
The problem with microarray experiments is that they are highly capable of 
generating long lists of genes with altered expression, but they provide little 
information as to which of these changes are important or results in a given 
phenotype. It is fair to say, that it is hard to predict the change of a given 
phenotype, when we see a shift of a single gene. Nevertheless, a dysregulation of 
genes within a functional group implies phenotypic changes, in particular when a 
significant shift occurs in an unidirectional manner.  
In this study we focused especially onto two gene groups, the one of the cell 
cycle/proliferation and apoptosis, because the balance of both functionally groups 
were significantly affected by ribozyme mediated modification of CEA levels. In 
addition, we focused our study on those two gene groups, because the balance of 
these two pathway is known to significantly affect tumor growth. 
However, the change of gene expression in the cell cycle/proliferation group and in 
the apoptosis group differed from each other. While in the cell cycle /proliferation 
group genes shifted in a bidirectionally manner, apoptotic genes were shifted in a 
unidirectional manner in the CEA down-regulated cells. None of the observed 
changes were seen in the tetracycline-treated control cell line (HT29/tTA-5).  
Because we saw a CEA dependent shift in gene expression in the cell 
cycle/proliferation group and in the apoptosis gene group the next step, we were 
pursuing, was to determine if that would result in a change in the phenotype of 
HT29 cells in vitro. Interestingly, the vast majority of apoptosis regulators (down-
regulated in the CEA expressing cells) are proapoptotic genes. However, at this 
point it is difficult to draw conclusions regarding particular genes affected by CEA 
and how CEA may interact within the apoptotic cascade.  
Studies regarding the apoptosis regulating function of CEA has been done already 
previously by Ordonez, C. et al. They described for the first time, that CEA might 
play a potential role of CEA in regulation of anoikis, a special type of apoptosis, 
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which is induced by loss of cell contact with the extracellular matrix. They 
demonstrated that forced overexpression of CEA and CEACAM6 on the surface of 
different cell lines (L6 rat myoblasts, MDCK epithelial cells, and human SW1222 
and Caco-2 colorectal cancer cells) inhibited their anoikis in vitro. They 
hypothesized, that the antiapoptotic effect could be a result of intercellular 
interactions mediated by binding of CEA to CEACAM6 on the cell surface 
(ORDONEZ, C. et al, 2000). However, the influence of CEA alone as an 
antiapoptotic molecule was not studied. 
In this study we demonstrated that CEA alone may have an important regulatory 
role in apoptosis. We are able to demonstrate a significant interaction between CEA 
and apoptosis–related gene expression and that endogenous CEA protects human 
HT29 cells from a variety of apoptotic stimuli. We suggest that CEA has a direct 
role in the regulation of apoptosis, but is also very much dependent on external 
factors including cell proximity to other CEA-expressing cells. For example, dense 
cell growth resulted in a significantly (2.5-fold) higher apoptotic rate in CEA-
depleted cells, whereas semiconfluent conditions did not significantly affect the 
apoptotic rate. Interestingly, when semiconfluent growing cells were treated with 
various inducers of apoptosis, including UV-light, IFN-γ and 5-FU (which is the 
main cancer drug for treatment of colorectal cancer), we could demonstrate a 
protective role of CEA. Basically, the protective and stabilizing effect of CEA 
could only be shown under condition of external stress. Otherwise, under normal 
condition there was no significant affect of CEA to the apoptotic rate of HT29 cells.  
Additional studies are needed to define the exact mechanism by which CEA 
protects against apoptosis. Because of the fact, that the expression of CEA on the 
cell surface of cancer cell is without an intracellular signaling moiety, we 
hypothesize that CEA may interact with other membrane molecules. For example, 
cell signaling (phosphorylation) could happen by binding of CEA to another protein 
( for example a receptor), which has a intracellular signaling moiety.  
In accordance with our microarray data, we found a significant change of the 
apoptotic rate between the CEA-reduced cells and the cells with normal CEA 
levels. But the cell cycle and proliferation rate did not differ between CEA-reduced 
and normal CEA-expressing cells.  
Our hypothesis is, that CEA-expressing colon cancer cells may have a growth 
advantage in patients because of the protective function of CEA, which can help 
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colon cancer cells to survive the hostile condition (external stress) they are exposed 
to during progression.  
We demonstrated an influence of CEA on the apoptotic rate in HT29 colon cancer 
cells. We hypothesized, that the protective effect of CEA, would result in a growth 
advantage for cells with higher CEA levels. We performed a proliferation assay, in 
order to see a probable difference in the proliferation rate, but the difference in the 
apoptotic rate did not seem to affect the proliferation rate of HT29 cells. After 72 
hours there was no difference in the proliferation rate between CEA-depleted cells 
and cells with normal CEA levels. The next step was to further analyze if the 
difference of apoptotic rate between the CEA-depleted cells and the cells 
expressing normal levels of CEA would influence the colony formation of HT29 
cells. We found out, that when we grew the HT29/Rz4 cells in soft agar and 
counted the number of colonies after two weeks the imbalance of proliferation and 
apoptosis resulted in a significant higher number of colony formation in cells with 
normal CEA levels. This would suggest the importance and the influence of CEA in 
tumor growth. Cells with normal CEA levels having a lower apoptotic rate than 
CEA-depleted cells would result in a growth advantage. Additionally, it is possible, 
that CEA could function besides as a protective factor also as an autocrine growth 
factor, which is released from tumor cells into the surrounding microenvironment.  
 
To compare the impact of CEA-dependent aggregation and apoptosis in vivo we 
analyzed the metastatic growth of HT29 cells in nude mice. We assumed that 
differences in aggregate formation would primarily alter the phase of tumor seeding 
which would occur within the first hours of tumor cell injection. Interestingly, one 
hour after tail vein injection of HT29/Rz4 tumor cells with high and low CEA 
levels, we found almost identical numbers of single cells and tumor cell aggregates 
in the lung. 24 hours later virtually all cells were eliminated in both groups. This 
finding could suggests that differences in aggregate formation in vitro had no 
significant impact on tumor cell seeding in vivo. In contrary, another very 
interesting theory is the “seed and soil”-hypothesis. Already over 100 years ago 
Paget noted a highly non-random spread of cancer to specific target organs. From 
these observations , he formulated the “seed” (primary cancer) and “soil” (target 
organ)-hypothesis of metastasis (PAGET, S. 1889). The “seed and soil”-hypothesis 
is about tumors, which can have enormously different characteristic metastatic 
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rates. In contrast to the variability in rates, there is a surprising degree of specificity 
in the target organs colonized by metastases from particular type of tumor. In the 
case of colorectal cancer they are known to most often target the liver, but they also 
do metastasize to the lung. In an animal study from Kuo, T.-H. et al, human colon 
tumors were transplanted into the nude mouse colon as intact tissue blocks by 
surgical orthotopic implantation. They used cells taken from a metastatic and non-
metastatic tumor. Both classes of tumors were equally invasive locally into tissues 
and blood vessels. However, the cells from each class of tumor behave very 
differently when injected directly into the mouse liver. Only cells from 
metastasizing tumors were competent to colonize after direct intrahepatic injection 
(KUO, T.-H. et al, 1995). 
However, 6 weeks after tumor cell injection, we detected in all mice which were 
treated with doxycycline enriched food to continuously block ribozyme expression, 
numerous lung metastases, while cells with ribozyme reduced CEA levels did not 
develop metastatic lesions in four out of five mice. These data suggest that CEA 
has its major effect when tumor cells have already seeded in their metastatic target 
organ. The question still is how CEA is involved in the pathway of metastasis. It 
has been shown, that CEA induces the production of cytokines, especially IL-6 and 
TNF-α (EDMINSTON, K. H. et al, 1997, GANGOPADHYAY, A. et al, 1998 and 
MINAMI, S. et al, 2001). The production of cytokines might result in a 
microenvironment, which is favorable for tumor cell growing. Previously there was 
a study that demonstrated in animal models, that human cancer cells find optimal 
growth conditions when placed orthotopically in their organ of origin, but show a 
higher apoptotic rate when placed as metastatic lesions (ENGLER, S. et al 2001). 
This would speak again for the importance of the microenvironment for tumor cell 
growing. Taking this all together with our in vitro data, i.e. increased apoptotic rate 
under external stress and reduced colony formation in CEA-depleted cells, it seems 
obvious that CEA plays a major role in colon cancer progression. 
 
At this point it is worth to mention, that all these results are not the result of 
unspecific binding, or cleavage of the ribozyme. Studies have been done to 
document the specificity of ribozymes. Werner, M. et al studied the effect of base 
mismatches in the substrate recognition helices of hammerhead ribozymes on 
binding and catalysis. They demonstrated that ribozymes lack already cleavage 
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activity if there is a mismatch of two or more nucleotides (WERNER, M. et al 
1995). In addition, the use of a highly specific target sequence, which is unique for 
the human carcinoembryonic antigen strongly emphasizes that the observed 
changes are ribozyme related and CEA specific. 
 
As mentioned earlier, CEA does not have an intracellular signaling moiety. 
Nevertheless, our finding, that CEA has a protective function against apoptosis, 
suggests that CEA has to operate indirectly through something else. 
The idea of CEA interacting with other molecules led us to the idea of screening for 
CEA and it’s binding to other proteins by using the phage display analysis.  
Phage display is based on the ability of bacteriophage to present protein fragments 
on their surface coat. Diverse libraries of proteins, for example cDNAs, may be 
displayed. Interactions between phage displayed proteins and target antigens can 
therefore be identified. The power of phage display is that it enables identification 
of candidate epitopes without knowledge of the protein interaction a priori. The 
basis of phage selection is an affinity interaction between the displayed protein and 
its target. Phage are prepared from the library, which is in our case a human colon 
cancer cell line (LS174T) and are selected against the antigen, or target, which is in 
our case CEA.  
One important issue in performing phage display analysis is, that the stringency of 
affinity selection is more or less opposed to yield, which is controllable in some 
degree by the choice of conditions. Yield is all-important in the first round of 
selection, but in later rounds yield can be sacrificed in the interest of stringency. 
There is a limit to stringency, however. The reason is that there is always a 
background yield of non-specifically bound phage; if stringency is set too high, the 
yield of specifically captured phage will fall far below the background of non-
specifically bound phage, and all power of discrimination in favor of high affinity is 
lost. In practice, because the relationship between selection conditions and 
stringency is unknown in advance, there might be the risk of loosing proteins which 
might be of interest.  
As a result of the phage display, we were able to demonstrate that specific binding 
between peptides (displayed as a fusion protein on phages) and CEA occurred. 
Furthermore, we were able to select these clones, which demonstrated specific 
binding to CEA. The results of the phage display suggests that CEA is able to 
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interact with different proteins, and therefore might be involved also in many 
different pathways, unknown before. Of course, the fact that there is specific 
binding of phages to CEA, does not automatically lead to the conclusion, that this 
specific binding has relevance in vitro or in vivo. Proteins might be in reality in 
different compartments of the cells and therefore never be able to interact with each 
other. Another critical factor is peptide scaffolding. Three dimensional structures 
might be formed which might lead to binding of your peptide to your target protein 
(RODI, D.J. and MAKOWSKI, L. 1999). This phenomenon has been described 
already and it is known as “mimotopes”.  
Even though phage display is a very powerful method the selection of proteins from 
a phage display analysis is just the first step of a big process. Whether binding to a 
specific protein is happening under normal circumstances would be the second step. 
And if there is binding, what is the result of it ?  
 
CEA seems to be involved in many different processes. In this study it was 
demonstrated to function as an adhesion molecule. In addition, it was demonstrated 
that CEA has protective function against apoptosis and that there is a CEA 
dependent gene expression in HT29 colon cancer cells. Tumor cells (with normal 
CEA levels), injected into the tail vain of nude mice, were able to form more 
metastatic lesions in the lung than cells with reduced CEA levels. 
 
In conclusion, this study demonstrates a multifunctional role of CEA in colon 
cancer cells, such as tumor cell aggregate formation and protection against 
apoptosis. We showed a significant interaction between CEA and apoptosis-related 
gene expression. The animal experiment suggests that the growth regulating effect 
of CEA is of importance for metastatic growth while aggregate formation plays a 
less significant role in tumor progression. Reduced apoptosis in cells with high 
levels of CEA after exposure to γ-interferon, or 5-FU suggests that inhibition of 
CEA expression may provide a novel therapeutic strategy to circumvent drug 
resistance. Further studies warranted which determine the signal transduction 
pathway of CEA and, thus, the therapeutic potential of treatment modalities 
targeting CEA and its related signaling pathway in cancer cells.  
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